Quest Diagnostics Nichols Institute 14225 Newbrook Drive Chantilly, VA 20151 QuestDiagnostics.com



RECEIVED

2012 MAY -9 AM 7:58

May 8, 2012

Ms. Roberta Wagner
Department of Administration Purchasing Division
2019 Washington Street East
Charleston, WV 25305-0130

WV PURCHASING DIVISION

Dear Ms. Wagner & Members of the West Virginia Department of Health & Human Resources:

Thank you for giving Quest Diagnostics the opportunity to respond to BHS12155 for laboratory services. As the nation's leading provider of diagnostic testing, Quest Diagnostics is uniquely positioned to meet your needs through our local Nichols Institute laboratory in Chantilly, Virginia.

Our RFQ response and pricing are attached. This proposal is contingent upon successful contract execution and we expect that the agreement resulting from this solicitation is consistent with our proposal and the clarifications to the proposed terms and conditions noted below.

General Terms & Conditions, RFQ & RFP

2. The State may accept or reject in part, or in whole, any bid.

Quest Diagnostics has proposed pricing based on the state's expected test mix and volumes. To be eligible for this pricing, the state of West Virginia Department of Health & Human Resources must utilize Quest Diagnostics for 80% of your testing.

4. All services performed or goods deliver under State Purchase Order/Contracts are to be continued for term of the Purchase Order/Contracts, contingent upon funds being appropriated by the Legislature or otherwise being made available. In the event funds are not appropriated or otherwise available for these services or goods this Purchase Order/Contract becomes void and of no effect after June 30.

It is the responsibility of the state to monitor funds for the contract. Quest Diagnostics will perform and bill for any ordered test.

• 13. HIPAA Business Associate Addendum: The West Virginia State Government HIPAA Business Associate Addendum (BAA), approved by the Attorney General, is available online at www.state.wv.us/admin/purchase/vrc/hipaa.html and is hereby made part of the agreement provided that the Agency meets the definition of a Cover Entity (45 CFR § 160.103) and will be disclosing Protected Health Information (45 CFR § 160.103) to the vendor.

Quest Diagnostics is a covered entity under HIPAA that complies in that capacity with the Privacy and Security Rules at 45 CFR Parts 160, 162, and 164. The "Position Paper" provided as Attachment 1 explains in further detail why Quest Diagnostics is not a business associate of our hospital or other clients when we perform clinical laboratory testing services.

◆ 14. Confidentiality: The vendor agrees that he or she will not disclose to anyone, directly or indirectly, any such personally identifiable information or other confidential information gained from the agency, unless the individual who is the subject of the information consents to the disclosure in writing or the disclosure is made pursuant to the agency's policies, procedures, and rules. Vendor further agrees to comply with the Confidentiality Policies and Information Security Accountability Requirements, set forth in http://www.state.wv.us/admin/purchase/privacy/noticeConfidentiality.pdf.

Quest Diagnostics maintains comprehensive data privacy and security programs. Compliance with the Health Insurance Portability and Accountability Act (HIPAA) is a significant element of the company's overall Compliance Program. In addition, Quest Diagnostics has a dedicated information security organization with defined roles and responsibilities and a management framework to control the implementation and operation of information security within the organization.

As a covered entity under HIPAA, Quest Diagnostics has implemented physical, administrative and technical safeguards which meet or exceed the requirements of the HIPAA rules related to data privacy and security (per 45 CFR Parts 160 & 164). These privacy and security activities are in place at Quest Diagnostics to maintain the confidentiality, integrity and availability of Protected Health Information.

We have reviewed the Confidentiality Policies & Information Security Accountability Requirements and have identified concerns with several provisions. Quest Diagnostics can agree to the terms set forth in that document, with the exception that there are some provisions (listed below) which we would need to modify to reflect our practices, and our representatives are willing to discuss these items further with your organization upon request.

- ♦ 4.3
- ♦ 4.3.2
- **♦** 4.4.1
- **♦** 4.4.2.1 − 4.4.2.2
- **♦** 4.4.2.4
- **♦** 4.5
- **♦** 4.6
- **♦** 4.7

Instructions to Bidders

♦ 2. Items offered must be in compliance with the specifications. Any deviation from the specifications must be clearly indicated by the bidder. Alternates offered by the bidder as EQUAL to the specifications must be clearly defined. A bidder offering an alternate should

attach complete specifications and literature to the bid. The Purchasing Division may waive minor deviations to specifications.

The tests in this bid have been converted (i.e. "mapped") to Quest Diagnostics' tests to the best of our ability based on the test description provided. Quest Diagnostics would welcome the opportunity to discuss any test in question in further detail in advance of or following contract award.

♦ 3. Unit prices shall prevail in case of discrepancy. All quotations are considered F.O.B. destination unless alternate shipping terms are clearly identified in the quotation.

Shipping terms of this nature are not applicable to the provision of a service such as laboratory testing. The state will be invoiced monthly for testing and services provided.

RFQ Terms

 Unless specific provisions are stipulated elsewhere in this contract document by the state of West Virginia, its agencies, or political subdivisions, the terms, conditions, and pricing set forth herein are firm for the life of the contract.

Quest Diagnostics has provided exceptions to the proposed terms and conditions in this letter. As previously stated, our proposal is contingent upon successful contract execution, and we expect that agreement resulting from this solicitation is consistent with this letter and our proposal.

The pricing for tests performed within the Quest Diagnostics network will be firm for the duration of the agreement. Tests referred to another reference laboratory are priced at the actual vendor test cost plus a \$25.00 handling fee and Quest Diagnostics shall have the right to increase charges to the state for any such tests in an amount that is commensurate with the increase by the reference laboratory.

Ordering procedure: Spending unit(s) shall issue a written state contract order (form WV-39)
to the vendor for commodities covered by this contract. The original copy of the WV-39 shall
be mailed to the vendor as authorization for shipment, a second copy mailed to the purchasing
division, and a third copy retained by the spending unit.

Quest Diagnostics will accept the written state contract order as the main contract document governing services. As stated above, we expect that agreement resulting from this solicitation is consistent with this letter and our proposal. Additional agreements may be required based on the services to be provided, such as Quest Diagnostics' standard connectivity agreement.

After the contract order is executed, individual test and phlebotomy orders will be required.

 The terms and conditions contained in this contract shall supersede any and all subsequent terms and conditions which may appear on any attached printed documents such as price Ms. R. Wagner & Members of the West Virginia Department of Health & Human Resources May 8, 2012 - Page 4 -

lists, order forms, sales agreements or maintenance agreements, including any electronic medium such as CD-ROM.

Quest Diagnostics has provided exceptions to the proposed terms and conditions in this letter. Our proposal is contingent upon successful contract execution, and we expect that agreement resulting from this solicitation is consistent with this letter and our proposal.

Further, our pricing terms as well as ordering terms and conditions such apply. Quest Diagnostics may require that the state sign additional contracts depending on the services to be performed, such as our IT Connectivity Agreement.

Local government bodies: Unless the vendor indicates in the bid his refusal to extend the prices, terms, and conditions of the bid to county, school, municipal and other local government bodies, the bid shall extend to political subdivisions of the state of West Virginia. If the vendor does not wish to extend the prices, terms, and conditions of the bid to all political subdivisions of the state, the vendor must clearly indicate such refusal in his bid. Such refusal shall not prejudice the award of this contract in any manner.

This bid shall not extend to other local government bodies. Quest Diagnostics would welcome the opportunity to bid on such opportunities separately.

Thank you again for giving Quest Diagnostics the opportunity to provide a response. We look forward to hearing from you.

Sincerely,

John Pickering, Hospital Account Executive 724-433-7430

John.D.Pickering@QuestDiagnostics.com

Charles Rippin, Hospital Sales Director 412-290-4188
Charles.F.Rippin@QuestDiagnostics.com



State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for PRONUMBER Quotation

BHS12155

PAGE
1

ADDITION OF THE PARTY OF THE PROPERTY OF THE PARTY OF THE

ROBERTA WAGNER 304-558-0067

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 350 350 CAPITOL STREET CHARLESTON, WV 25301-3702 304-558-3672

RFQ COPY TYPE NAME/ADDRESS HERE Quest Diagnostics Nichols Institute, Inc.

14225 Newbrook Drive

Chantilly, VA 20151

DATE PRINTED TERMS OF SALE SHIP VIA FO.8..... FREIGHT TERMS 04/05/2012 BID OPENING DATE: 05/09/2012 BID OPENING TIME 01:30PM LINE ITEM NUMBER: QUANTITY UOP UNIT PRICE AMOUNT THE STATE OF WEST VIRGINIA AND ITS AGENCY THE DEPARTMENT OF HEALTH AND HUMAN RESOURCES (DHHR), BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES (BHHF), AND THE SEVEN STATE OWNED AND OPERATED FACILITIES LISTED BELOW REQUEST A QUOTE TO PROVIDE LABORATORY SERVICES PER THE ATTACHED SPECIFICATIONS. THIS IS A RE-BID OF BHS12088. THE STATE OWNED AND OPERATED FACILITIES ARE: JACKIE WITHRO HOSPITAL HOPEMONT HOSPITAL 105 S. EISENHOWER DRIVE 150 HOPEMONT DRIVE BECKLEY, WV 25801 TERRA ALTA, WV 26764 LAKIN HOSPITAL JOHN MANCHIN SR. HEALTH 11522 OHIO RIVER ROAD CARE CENTER WEST COLUMBIA, WV 25287 401 GUFFEY STREET FAIRMONT, WV 26554 WELCH COMMUNITY HOSPITAL 454 MCDOWELL STREET MILDRED MITCHELL-WELCH, WV 24801 BATEMAN HOSPITAL 1530 NORWAY AVE. WILLIAM R. SHARPE, JR. HUNTINGTON, WV 25709 HOSPITAL 9B6 SHARPE HOSPITAL ROAD WESTON, WV 26452 *****BID OPENING: MAY 9, 2012 AT 1:30 PM LOCATION: PURCHASING DIVISION, BUILDING #15 2019 WASHINGTON STREET, EAST CHARLESTON, WV 25305 SEE REVERSE SIDE FOR TERMS AND CONDITIONS DATE 05/02/12 703-802-6900 FEIN 54-0854787 Managing Director ADDRESS CHANGES TO BE NOTED ABOVE



RFQ COPY

14225 Newbrook Drive

Chantilly, VA 20151

TYPE NAME/ADDRESS HERE

Quest Diagnostics Nichols Institute, Inc.

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for Quotation

BHS12155

PAGE

ADDRESSIONHESPONDENGERIOTATRIENTIONICE

ROBERTA WAGNER 304-558-0067

HEALTH AND HUMAN RESOURCES ВВН/НF

ROOM 350

350 CAPITOL STREET CHARLESTON, WV

25301-3702

304-558-3672

DATÉ PRINTEO	TERMS OF SALE	SHIP VIA	F.O.B.	FREIGHT TERMS
04/05/2012				
BID OPENING DATE: 05/0	9/2012	BID C	PENING TIME	01:30PM
LINE QUANTITY	UOP CAT NO	ITEM NUMBER	UNIT PRICE	AMOUNT
0001	YR :	00		
· •	1 1	193-88	See Attached.	See Attached.
1	- 1	EFERENCE LABORAT		- Joor Macrica.
		DE DICEITOD DADOIGHI	OKI DEKVICED	j ·
VENDOR TO	PROVIDE LABOR	ATORY SERVICES T	0	-
		TMENT OF HEALTH		
		ACILITIES WHICH	INCLUDE:	
	R SHARPE, JE			
		EMAN HOSPITAL	,	
	WITHROW HOSPI	TAL		
	OSPITAL OMMUNITY HOSE	T-1113 T		<u> </u>
I	ommoniii hose T Hospital	LIAL		· .
		LTH CARE CENTER		
	DIG. IIDI	DIN CARD CONTER		
PER THE AT	TACHED SPECIE	ICATIONS. THIS I	S A RE-BID OF	
BHS12088.				
		,		
·				
EXHIBIT 3				
		S CONTRACT BECOM		
		FOR A PERIOD OF		<u> </u>
		SONABLE TIME" THE CONTRACT OR R		;]
ORIGINAL CO		"REASONABLE TIM		т
	TWELVE (12)		THIS "REASONAE	
		RMINATE THIS CON		,44
		DIRECTOR OF PURC		; }
WRITTEN NOT				i i
UNLESS SPEC	CIFIC PROVISI	ONS ARE STIPULAT	ED ELSEWHERE	
		NT BY THE STATE		·
, ATRGINIA,	LTS AGENCIES,	OR POLITICAL SU	BDIVISIONS, TH	Œ
		 VERSE SIDE FOR TERMS AND COI	NDV//ANC	
SIGNATURE	JLE NE	TELEPHONE -		DATE 05/02/12
TIPE WALL OF CHE	ICEIN		03-002-0900	00/02/12
Managing Director	FEIN 54-0854787		ADDRESS CHA	NGES TO BE NOTED ABOVE
MUEN DECDOND	NO TO DECLINOED	T NAME AND ADDRESS	INCOMOR ADOVED A	DELEC BACKINADI



State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for Quotation BHS12155

PAGE 3

ADDRESS CORRESPONDENCE TO THE INTO NO.

ROBERTA WAGNER 304-558-0067

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 350 350 CAPITOL STREET CHARLESTON, WV 25301-3702 304-558-3672

RFQ COPY TYPE NAME/ADDRESS HERE Quest Diagnostics Nichols Institute, Inc. 14225 Newbrook Drive Chantilly, VA 20151

DATE PRINTED	TERMS OF SA	LE SHII	VIA	FOB	FREIGHTTERMS
04/05/2012					
BID OPENING DATE:	05/09/2012		BID OP	ENING TIME 0	1:30PM
LINE QUI	ANTITY UOP	CAT ITEM N	UMBER	UNIT PRICE	AMGUNT
		AND PRICING		HEREIN ARE	
FIRM FO	OR THE LIFE	OF THE CONTRA	CT.		
		L			
				ON THE MUTUAL	
		THE SPENDING			·
		TRECTOR OF PU			
				RENEWAL SHALL	
				OTTIONS OF THE	
		AND SHALL BE	TIMILED U	O TWO (2) ONE	,
(1) YEA	AR PERIODS.				·
CANCEL		DIDECTOR OF T	TTDGUAGTNG	RESERVES THE	
\$ I	i i	a i	4	, RESERVES THE Y UPON WRITTEN	
				AND/OR SERVICE	
1	1			O NOT CONFORM	2
מחם שת שתם	ED AKE OF AN	NAC OF THE DI	DAND COM	TRACT HEREIN.	
IN THE	DEECTERCH!	DNS OF ITE BI	D AND CON	IRACI ABABIN.	
OPEN MA	ARKET CLAUSE	: THE DIRECTO	R OF PURC	HASTNG MAY	
		NG UNIT TO PU			
1	1	E FILING OF A			***
		ECIFIED ON TH			
1	,	IN EMERGENCI			-
1		1 1		AYS IN TRANS-	
	•	ANTICIPATED I			
OF WORE		,			
		TIES LISTED I			
		Y, BASED ON E			1
				OD AND AGREED	
				TIES ACTUALLY	
				THE CONTRACT,	
WHETHER	R MORE OR LE	ss than the c	UANTITIES	SHOWN.	
	vid DDOGBDIIDI	OPENDANC IN	TTT (G) G TTT	I TOOTTO 3	
		: SPENDING UN RACT ORDER (F			
		MODITIES COVE			
1		SEE REVERSE SIDE FOR			l .
SIGNATURE		AAAAA	TABLE MALLES IN		^E 05/02/12
Managing Director	FEIN 54-0	<u>854787</u>		ŧ	SES TO BE NOTED ABOVE



Managing Difector

RFQ COPY

14225 Newbrook Drive

Chantilly, VA 20151

TYPE NAME/ADDRESS HERE

Quest Diagnostics Nichols Institute, Inc.

State of West Virginia Department of Administration Quotation **Purchasing Division** 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for

BEQ NUMBER BHS12155

MANDELES CONSESSIONES NO EN CONTROL NO ESTA DE LA CONTROL NOTROL NO ESTA DE LA CONTROL N

ROBERTA WAGNER

304-558-0067

HEALTH AND HUMAN RESOURCES BBH/HF

ROOM 350 350 CAPITOL STREET CHARLESTON, WV

25301-3702

304-558-3672

ADDRESS CHANGES TO BE NOTED ABOVE

DATE PRINTED TERMS OF SALE SHIP VIA F.O.B. 04/05/2012 BID OPENING DATE: 05/09/2012 BID OPENING TIME 01:30PM LINE QUANTITY. UOP ITEM NUMBER AMOUNT UNIT PRICE THE ORIGINAL COPY OF THE WV-39 SHALL BE MAILED TO THE VENDOR AS AUTHORIZATION FOR SHIPMENT, A SECOND COPY MAILED TO THE PURCHASING DIVISION, AND A THIRD COPY RETAINED BY THE SPENDING UNIT. BANKRUPTCY: IN THE EVENT THE VENDOR/CONTRACTOR FILES FOR BANKRUPTCY PROTECTION, THE STATE MAY DEEM THE CONTRACT NULL AND VOID, AND TERMINATE SUCH CONTRACT WITHOUT FURTHER ORDER. THE TERMS AND CONDITIONS CONTAINED IN THIS CONTRACT SHALL SUPERSEDE AMY AND ALL SUBSEQUENT TERMS AND CONDITIONS WHICH MAY APPEAR ON ANY ATTACHED PRINTED DOCUMENTS SUCH AS PRICE LISTS, ORDER FORMS, SALES AGREEMENTS OR MAINTENANCE AGREEMENTS, INCLUDING ANY ELECTRONIC MEDIUM SUCH AS CD-ROM. REV. 01/17/2012 ANY INDIVIDUAL SIGNING THIS BID IS CERTIFYING THAT: (1) HE OR SHE IS AUTHORIZED BY THE BIDDER TO EXECUTE THE BID OR ANY DOCUMENTS RELATED THERETO ON BEHALF OF THE BIDDER, (2) THAT HE OR SHE IS AUTHORIZED TO BIND THE BIDDER IN A CONTRACTUAL RELATIONSHIP, AND (3) THAT THE BIDDER HAS PROPERLY REGISTERED WITH ANY STATE AGENCIES THAT MAY REQUIRE REGISTRATION. NOTICE SIGNED BID MUST BE SUBMITTED TO: DEPARTMENT OF ADMINISTRATION PURCHASING DIVISION BUILDING 15 2019 WASHINGTON STREET, EAST CHARLESTON, WV 25305-0130 SEE REVERSE SIDE FOR TERMS AND CONDITIONS TELEPHONE 703-802-6900 DATE 05/02/12

54-0854787



DATE PRINTED

RFQ COPY

14225 Newbrook Drive

Chantilly, VA 20151

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

Request for ______REQ NUMBER Quotation

BHS12155

.....PACE 5

FREIGHT TERMS

ADDRESSROBBESENDENGENOTATE (TATELONG)

ROBERTA WAGNER 304-558-0067

TYPE NAME/ADDRESS HERE Quest Diagnostics Nichols Institute, Inc.

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 350 350 CAPITOL STREET CHARLESTON, WV 25301-3702 304-558-3672

04/05/2012					
BID OPENING DATE: 0	5/09/2012		BID C	PENING TIME	01:30PM
LINE QUAN	ITITY UOP	CAT. ITE	M NUMBER	UNITPRICE	AMOUNT
			,		
					ļ
THE BID	SHOULD CON	TAIN THIS I	NFORMATION	ON THE FACE	OF
THE ENV	ELOPE OR TH	E BID MAY N	OT BE CONS	IDERED:	
ĺ					
SEALED	BID				,
		·			·
.				,	
UYER:		ROBERTA W	AGNER/FILE	22	
		,			
RFQ. NO	.:	BH\$12155			
EID OPE	NING DATE:	MAY 9, 20	12		
`					
EID OPE	NING TIME:	1:30 PM			
				•	
Vietnament in the control of the con					***************************************
				IS NECESSARY	
TO CONT.	ACT YOU REG	ARDING YOUR	BID:		· · · · · · · · · · · · · · · · · · ·
6	10-271-8814				
					· ·
CONTACT	PERSON (PL	EASE PRINT	CLEARLY):		
	ohn Pickerina. Ho	spital Account Exe	ecutive		
	~~~~				
	1				
				,	
THE MOD	el/brand/sf	ECIFICATION	S NAMED HE	REIN ESTABLISI	H.
		EL OF QUALI			
		T A PREFERE			
				O ARE BIDDING	
		SO STATE AN			
		CIFICATIONS		TO PROVIDE	
		Y ALTERNATE			
REJECTIO	ON OF THE B			ES THE RIGHT	
/		SEE REVERSE SIDE			
SIGNATURE ///	P)		TELEPHONE 7	03-802-6900	DATE 05/02/12
Managing Director	FEIN 54-08	854787		ADDRESS CHA	INGES TO BE NOTED ABOVE
Wallaging Director		NOEDTAIALE		MODICO OTA	



HODOK

RFQ COPY

14225 Newbrook Drive

Chantilly, VA 20151

TYPE NAME/ADDRESS HERE

Quest Diagnostics Nichols Institute, Inc.

State of West Virginia Department of Administration **Purchasing Division** 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

## Request for Quotation

BHS12155

waddressioorisieseondevoeriovariaviiovio

ROBERTA WAGNER <u> 304-558-0067</u>

HEALTH AND HUMAN RESOURCES BBH/HF

**ROOM 350** 350 CAPITOL STREET CHARLESTON, WV

> 25301-3702 304-558-3672

> > ADDRESS CHANGES TO BE NOTED ABOVE

DATE PRINTED TERMS OF SALE 04/05/2012 BID OPENING DATE: 05/09/2012 BID OPENING TIME 01:30PM UOP LINE QUANTITY ITEM NUMBER: AMOUNT UNITPAICE to waive minor irregularities in bids or specifications IN ACCORDANCE WITH SECTION 148-1-4(F) OF THE WEST IRGINIA LEGISLATIVE RULES AND REGULATIONS. PURCHASING CARD ACCEPTANCE: THE STATE OF WEST VIRGINIA turrently utilizes a visa purchasing card program whic S ISSUED THROUGH A BANK. THE SUCCESSFUL VENDOR Must accept the state of west virginia visa purchasing card for payment of all orders placed by any state GENCY AS A CONDITION OF AWARD. EXHIBIT 4 **LOCAL GOVERNMENT BODIES:** UNLESS THE VENDOR INDICATES N THE BID HIS REFUSAL TO EXTEND THE PRICES, TERMS, AND CONDITIONS OF THE \$ID TO COUNTY, SCHOOL, MUNICIPAL AND OTHER LOCAL GOVERNMENT BODIES, THE BID SHALL EXTEN O POLITICAL SUBDIVISIONS OF THE STATE OF WEST IF THE VENDOR DOES NOT WISH TO EXTEND THE IRGINIA. PRICES, TERMS, AND CONDITIONS OF THE BID TO ALL #OLITICAL SUBDIVISIONS OF THE STATE, THE VENDOR MUST dlearly indicate such refusal in his bid. SUCH REFUSAL SHALL NOT PREJUDICE THE AWARD OF THIS CONTRACT IN ANY MANNER. REV. 3/88 INQUIRIES: Written Questions shall be accepted through close of dusiness on d4/24/2012. QUESTIONS MAY BE SENT VIA USPS, FAX, COURIER OR H-MAIL. IN ORDER TO ASSURE NO ENDOR RECEIVES AN UNFAIR ADVANTAGE, NO SUBSTANTIVE UESTIONS WILL BE ANSWERED ORALLY. IF POSSIBLE, E-MAIL QUESTIONS ARE PREFERRED. ADDRESS INQUIRIES TO: SEE REVERSE SIDE FOR TERMS AND CONDITIONS SIGNATURE DATE 05/02/12 703-802-6900

54-0854787

Managing Director



RFQ COPY

14225 Newbrook Drive

Chantilly, VA 20151

TYPE NAME/ADDRESS HERE

Quest Diagnostics Nichols Institute, Inc.

State of West Virginia
Department of Administration
Purchasing Division
2019 Washington Street East
Post Office Box 50130 Charleston, WV 25305-0130

# Request for PRONUNCER Quotation

BHS12155

PAGE ..... 7

ADDRESS CORRESPONDENCE TO ATTENTION OF

ROBERTA WAGNER 304-558-0067

HEALTH AND HUMAN RESOURCES BBH/HF **ROOM 350** 

350 CAPITOL STREET CHARLESTON, WV

25301-3702 304-558-3672

DATE PRINTED TO	HMS OF SALE	SHIP VIA		F.O.8,	FREIGHT TERMS
04/05/2012					
BID OPENING DATE: 05/09		BII	) OPI		1:30PM
LINE QUANTITY	UOP CAT NO	ITEM NUMBER		UNIT PAICE	AMOUNT
ROBERTA WAGI DEPARTMENT ( PURCHASING I 2019 WASHING CHARLESTON,	OF ADMINIST DIVISION STON STREET WV 25311				
FAX: (304) 5 E-MAIL: ROBI		R@WV.GOV			·
A CERTIFICATE BY THE SUCCE	TE OF WORKER	RS COMPENSATION CR.	WIL	L BE REQUIRED	
***** <b>THTS</b>	TC TOLE DAY	OF DEC. DVG	01-5		Ku mar Con i i in
J. C. C. THIE	TS THE EN	OF RFQ BHS1	2155	****** TOTAL:	\$475,821.10
	SEE AE	VERSE SIDE FOR TERMS AND			
SIGNATURE / ///		TÉLEPHÔNE	703-8	302-6900 DATE	05/02/12
Managing Director	54-0854787			ADDRESS CHANGE	S TO BE NOTED ABOVE



State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

# Request for REQNUMBER BHS12155

PA0	38
	1

ADDRESS CORRESPONDENCE TO ATTENTION OF ROBERTA WAGNER 304-558-0067

25301-3702

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 350 350 CAPITOL STREET CHARLESTON, WV

304-558-3672

RFQ COPY TYPE NAME/ADDRESS HERE Quest Diagnostics Nichols Institute, Inc.

14225 Newbrook Drive Chantilly, VA 20151

04/25/2	<u> </u>	rims of sale	\$HIP VIA	F.O.B.	FREIGHTTERMS
BID OPENING DATE:	05/09/	2012	I BTD O	PENING TIME	01:30PM
LINE	QUANTITY	UOP CAT.	ITEM NUMBER	UNIT PRICE	AMOUNT
		1,00			
		ADDENI	UM NO. 1		
	A-1				
1 1		<b> </b>	S ARE ATTACHED. MENT IS ATTACHED	THIS DOCUME	אַת
1 5		1 1	TURNED WITH YOUR		,
			ULT IN DISQUALIE		
E	ID.				
	XHIBIT 10				
-1	mana 10				
			REQUISITION N	O.: BHS12155	
ות	DDENDUM ACK	SOUT ELCEMEN	m		
]	DDENDOM ACK	NOWLELGEMEN	<b>1</b>		
1	HEREBY ACK	OWLEGE RE	CEIPT OF THE FOL	LOWING CHECKE	D
			DE THE NECESSARY		
l M	Y PROPOSAL,	PLANS AND/	OR SPECIFICATION	, ETC.	
A)	DDENDUM NO.	ls:			
	0. 1. X				4474
17	0, 2	* -			
N	0. 3	.[. ]			
N	0, 4,	•			
N	0. 5	.].			
]			RE TO CONFIRM TH		
[	HE ADDENDUM	(S) MAY BE	CAUSE FOR REJECT	LON OF BIDS.	
•					
					!
SIGNATURE / / / F	<i>0</i> 77 :	SEE AE	VERSE SIDE FOR TERMS AND CON TELEPHONE		DATE OS/OD/AD
III III	Illue	acist	TELEPHONE 70		05/02/12
Managing Di	irector	^{FEIN} 54-0854787		ADDRESS CHA	ANGES TO BE NOTED ABOVE



RFQ COPY

14225 Newbrook Drive

Chantilly, VA 20151

TYPE NAME/ADDRESS HERE

Quest Diagnostics Nichols Institute, Inc.

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

# Request for REGNUMBER Quotation

BHS12155

×	γ\ĠΕ
	2

ADDRESS CORRESPONDENCE TO ATTENTION OF ROBERTA WAGNER 304-558-0067

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 350 350 CAPITOL STREET

CHARLESTON, WV 25301-3702 304-558-3672

ADDRESS CHANGES TO BE NOTED ABOVE

FREIGHT TERMS SHIP VIA ........... F.O.Β... DATE PRINTED TERMS OF SALE 04/25/2012 BID OPENING DATE: 01:30PM BID OPENING TIME 05/09/2012 ÇAT NO. AMOUNT: ITEM NUMBER UNIT PAICE LINE QUANTITY ÜÖP VENDOR MUST CLEARLY UNDERSTAND THAT ANY VERBAL REPRESENTATION MADE OR ASSUMED TO BE MADE DURING ANY dral discussion held between vendor's Representatives AND ANY STATE PERSONNEL IS NOT BINDING. ONLY THE INFORMATION ISSUED IN WRITING AND ADDED TO THE SPECIFICATIONS BY AN OFFICIAL ADDENDUM IS BINDING. SIGNATURE Quest Diagnostics Nichols Institute, Inc. COMPANY 05/02/12 DATE NOTE: THIS ADDENDUM ACKNOWLEDGEMENT SHOULD BE SUBMITTED WITH THE BID. REV. 09/21/2009 END OF ADDENDUM NO. 1 SEE REVERSE SIDE FOR TERMS AND CONDITIONS TELEPHONE 703-802-6900 O5/02/12

54-0854787

Maňaging Director



DATE PRINTED

State of West Virginia Department of Administration Purchasing Division 2019 Washington Street East Post Office Box 50130 Charleston, WV 25305-0130

TERMS OF SALE

# Request for REGNUMBER Quotation

SHIP VIA

BHS12155

PAGE 3

FRÉIGHT TERMS

ADDRESS CORRESPONDENCE TO ATTENTION OF HOBERTA WAGNER

304-558-0067

RFQ COPY TYPE NAME/ADDRESS HERE **Quest Diagnostics Nichols Institute** 14225 Newbrook Drive Chantilly, VA 20151

HEALTH AND HUMAN RESOURCES BBH/HF ROOM 3 ROOM 350 350 CAPITOL STREET CHARLESTON, WV 25301-3702 304-558-3672

F.O.B.

04/25/								
BID OPENING DAT	E: (	05/09/2	012			BID C	PENING TIME	01:30PM
LINE	QUA	NTITY	. UOP	ČAŤ, NO.	JTEM NU	MBER	UNIT PRICE	AMOUNT
001	CPEN EN	1	R RACT	1	93-88 EFERENCE	LABORAT	See attached. ORY SERVICES	See attached.
The residence and the second and the	*****	THIS	IS TH	E ENC	OF RFQ	BHS121	55 ***** TOT?	ML: \$475,821.10
SIGNATURE / ,				See ae	VERSE SIDE FOR	Terrentiate		DATE:
1 117	w/le	29	111			Transport 7	<del>,</del>	DATE 05/02/12
Managing				354787				NGES TO BE NOTED ABOVE
		ONDING	TO RFQ	. INSER	T NAME AND	ADDRESS	IN SPACE ABOVE LA	BELED 'VENDOR'

## Open End Contract for Reference Laboratory Services BHS11095

## 1.1 Purpose:

To provide reference laboratory services to the West Virginia Department of Health and Human Resources (WV DHHR), Bureau for Behavioral Health and Health. Facilities (BHFF), State owned facilities which include: William R. Sharpe, Jr. Hospital, Mildred Mitchell Bateman Hospital, Jackie Withrow Hospital, Lakin Hospital, Welch Community Hospital, Hopemont Hospital, and John Manchin Sr. Health Care Center, hereafter referred to as "facilities".

## Location of Facilities:

Jackie Withrow Hospital 105 S. Eisenhower Drive Beckley, WV 25801

Lakin Hospital 11522 Ohio River Rd Lakin, WV 25287

Welch Community Hospital 454 McDowell Street Welch, WV 24801

William R. Sharpe, Jr. Hospital 936 Sharpe Hospital Road Weston, WV 26452 Hopemont Hospital 150 Hopemont Drive Terra Alta, WV 26764

John Manchin Sr. Health Care Center 401 Guffey Street Fairmont, WV 26554

Mildred Mitchell-Bateman Hospital 1530 Norway Ave. Huntington, WV 25709

## 1.2 Mandatory Requirements

1.2.1 Vendor shall provide reference laboratory services to the above listed State owned facilities

Quest Diagnostics is the nation's leading provider of diagnostic testing, information, and services. Our Nichols Institute laboratory in Chantilly, Virginia, has more than adequate capacity and staffing to provide reference laboratory services to the seven WV DHHR facilities listed above.

1.2.2 Vendor must establish connectivity with the Data Innovations server, and compatibility with the Instrument Manager software used by the state and facilities within ninety (90) days of the start of the contract. This will create a Health Level Seven (HL7) format, bidirectional interface between the vendor and the Electronic Patient Record System for the flow of facility lab orders to the vendor and lab results from the vendor.

Quest Diagnostics will work with the WV DHHR to implement a bidirectional LIS-LIS interface between our laboratory information system and yours. Every effort

will be made to implement the interface within 90 days of contract award, though the average interface build takes approximately 90-120 days. A sample interface build plan is attached as Attachment 2; this sample plan is based on a standard interface implementation with no development and a 200-test dictionary build.

We support standard HL7 protocol and in general, are interfaces are based on HL7 2.3 protocol (earlier versions of HL7 are also supported). While ASTM protocol is not currently the standard, we do support it as well.

1.2.3 Vendor shall develop and maintain a process to supply printed laboratory results to a designated printer at each facility in the event of any issues inhibiting the transfer of data through Medsphere Open VistA

Quest Diagnostics invites each WV DHHR facility associated with this RFQ to use our Care360 Lab Orders & Results (LO&R) connectivity solution for web-based ordering and resulting. While Care360 LO&R can be the primary ordering tool, it often supplements an existing LIS interface. It can be used for ordering tests that have not been built in the interface or for order entry while the interface is under development.

With Care 360 LO&R, our customers can:

- Order lab tests and receive results electronically through a web-enabled PC; simultaneous user access through networked PCs is also supported
- Access patient and test information anytime from any computer with an Internet connection
- Use customizable screens when placing standing orders or submitting requisitions for frequently ordered tests
- Utilize advanced reporting features, such as cumulative graphing and the ability to retrieve and print test results by patient, date, test, or abnormal result
- Access our current Directory of Services as well as ICD and CPT codes
- Order supplies
- Protect patient information and adhere to privacy regulations; Care360 LO&R meets all proposed Health Insurance Portability and Accountability Act (HIPAA) standards and protects patient information with 128-bit encryption and the services of Verisign™, an industry leader in system security verification
- 1.2.4 Vendor shall ensure that all laboratory policies and procedures comply with the regulations of the Health Insurance Portability and Accountability Act (HIPAA).

As a covered entity under HIPAA, Quest Diagnostics has put in place standards and procedures to ensure that our security and privacy standards are compliant with applicable laws. Integral components of our HIPAA compliance activities are employee training and the implementation of minimum necessary access to protected health information requirements, to reduce the risk of inappropriate exposure of protected health information. All 43,000+ employees have been

trained on HIPAA and data privacy, and also have signed an Integrity Commitment, promising to protect the privacy of all patient health information. We have entered into business associate agreements with vendors who provide certain services to us (where they will have access to protected health information on our behalf) in which the vendors agree to meet the privacy requirements of a HIPAA-covered entity. In addition, our information technology department security experts, in consultation with outside experts, have developed and implemented technical standards to help ensure the security of protected health information.

Please visit <u>www.questdiagnostics.com</u> to view our Privacy Policy and Notice of Privacy Practices.

1.2.5 Vendor shall provide current copies of Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certificates. The vendor shall maintain on-going certification by (CLIA) and (CAP) and provide copies of certificates upon any renewals which occur during the contract period.

Each Quest Diagnostics laboratory is fully accredited in line with all applicable federal and state statutes. At Quest Diagnostics Nichols Institute Chantilly, this includes accreditation by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certification.

Current copies of the laboratory's CAP and CLIA certificates are attached as Attachment 3. During the contract period, updated certificates can be provided to the WV DHHR as these accreditations expire and are renewed.

1.2.6 Vendor shall maintain compliance with (CLIA) regulations that address specimen rejection and the categorization of specimens as unsatisfactory.

As stated above, Quest Diagnostics Nichols Institute Chantilly is fully accredited and licensed. The laboratory adheres to all applicable CLIA and CAP standards and requirements.

1.2.7 Vendor shall ensure that all information provided in the laboratory reports complies with (CAP) standards.

As stated above, Quest Diagnostics Nichols Institute Chantilly is fully accredited and licensed. The laboratory adheres to all applicable CLIA and CAP standards and requirements.

When applicable and assuming that complete and accurate information was submitted at the time of the original test order, the following information is generally included on patient result reports:

- Patient identifying information (name, date of birth, etc.)
- Referring physician name
- Specimen accession number

- Specimen type (depending on specific test)
- Date of collection
- Date of test order
- Date of test report
- Name and address of performing laboratory
- Test name/code
- Result and interpretation (includes flags and reference ranges where appropriate)
- 1.2.8 Vendor shall maintain compliance with (CLIA) regulations regarding Quality Control and Quality Assurance, including documentation of the vendor's proficiency testing program. The vendor shall provide all such documentation to BHFF, or its individual facilities, upon request.

Extensive quality assurance and quality control programs are in place at each Quest Diagnostics laboratory consistent with all applicable CLIA requirements. These programs include comprehensive proficiency testing procedures.

In general, specific quality data not provided to customers. However, such data may be shared on-site at the Quest Diagnostics performing laboratory to the extent we do not consider the requested data to be confidential and proprietary.

1.2.9 Vendor shall maintain stored lab results for Quality Assurance monitoring and assessment of laboratory services for the current time periods mandated by regulatory bodies (CAP and CLIA).

Specimen retention times vary based on criteria such as state and federal regulations, test manufacturer's recommendations, deterioration of the analyte, and CAP and CLIA requirements. However, generally specimens are retained for 10-14 days following test completion.

1.2.10 Vendor shall maintain all specimen and report data in electronic format, including the total number of tests performed on a daily, monthly and annual basis by individual testing category. Vendor shall provide all such comprehensive or individual facility statistical reports to BHHF, or each individual facility, upon request.

Electronic utilization reports are available upon request each month at the facility-level and will include the following information for each ordered test: test name, test code, quantity ordered, unit cost, and total cost. Monthly and year-to-date data are provided.

1.2.11 Vendor shall employ a Board Certified Pathologist who is to be made available seven days each week, during normal working hours, for questions and/or interpretation of test results. The full Quest Diagnostics network has over than 700 pathologists across the country and many of those pathologists based at the Nichols Institute laboratory in Chantilly, Virginia. Board-certified pathologists are available twenty-four hours a day, 365 days a year to provide consultative or interpretive information.

1.2.12 Vendor shall provide the facilities, on an on-going basis, with the name, address, and telephone number of their account representatives. Vendor shall also provide the facilities with a telephone referral service (twenty four hours a day/seven days a week) (24/7) for the purpose of responding to facility inquires that require technical or professional support.

## **Local Account Management Team**

Quest Diagnostics recognizes and is committed to meeting the special needs of hospitals. To that end, our Hospital Services organization is separately managed and dedicated only to hospital business. Representatives are deployed strategically across the country by geography and customer density to achieve the most effective combination of service, and each hospital we serve is assigned a management team comprised of multiple account representatives from this specialized organization.

Each WV DHHR facility associated with this RFQ will be assigned account representatives from this specialized organization.

## Telephone Support (Client Services)

Quest Diagnostics Nichols Institute Chantilly's Client Services representatives are available by telephone 24 hours a day, 365 days a year to respond to inquiries in areas such as specimen requirements, general test information, turnaround time, test add-ons, and results. Client Services representatives will also channel calls to the appropriate individuals (including medical directors, scientific directors, and pathologists) for technical or medical interpretive information.

1.2.13 Vendor shall provide a set fee for phlebotomy services to be provided at the designated facilities. When, and/or if, a phlebotomist is needed, the facility will contact the vendor for the provision of services pursuant to the fee quoted. Please note: all travel expenses, if any, must be included in the fee as an all inclusive rate.

Quest Diagnostics can provide phlebotomy services on-site as needed with sufficient prior notice to the seven WV DHHR facilities associated with this RFQ. Our typical method of billing Phlebotomy is on a per patient basis.

Estimated charges inclusive of travel have been included in Exhibit B. Please note, these charges were developed based upon the WV DHHR's estimated service requirements. We reserve the right to renegotiate the hourly charge as appropriate.

1.2.14 Vendor shall provide daily collection (courier) services seven (7) days per week

at each facility for pick-up and transport of specimens. Services shall be performed by individuals specifically trained in laboratory specimen transport including the rules and regulations (Department of Transportation 49 Code of Federal Regulations, Parts 171-178) related to the transport of clinical specimens. Collection times shall take into consideration the facilities' needs for optimal test result turnaround times.

The Quest Diagnostics courier force includes 4000 personnel, 3500 vehicles, and a private fleet of more than 20 aircraft. This extensive logistics network allows for great flexibility.

All of our Route Service Representatives (RSRs) are fully trained and perform duties in line with all applicable federal requirements.

At no addition charge, we can provide one scheduled daily (Monday – Sunday) pickup at each of the seven facilities participating in this RFQ.

1.2.15 Vendor shall assume responsibility and liability for examining, interpreting, and reporting results of all specimens.

Quest Diagnostics will be responsible and liable for examining, interpreting, and result reporting of all specimens referred to our laboratories for ordered testing to the extent applicable. Testing will be performed in line with our existing policies and procedures.

1.2.16 Vendor shall provide the facilities with written instructions regarding patient preparation, proper specimen collection, specimen identification, specimen preservation, and specimen transport. Vendor will supply on-site training of facility staff as needed.

Instructions (Directory of Services)

Our Directory of Services includes comprehensive instructions for preparing, collecting, and submitting specimens to Quest Diagnostics for testing. The Directory may be accessed online at <a href="https://www.nicholsinstitute.com">www.nicholsinstitute.com</a> and is also available in hard copy upon request.

On-Site Training

To make the transition from another reference laboratory to Quest Diagnostics Nichols Institute Chantilly as easy as possible, we designed our "Smooth Start" program. This transition program typically includes orientation and education on a variety topics such as specimen collection and preparation, test ordering and requisitions, supplies, results, and key contacts. The program is fully customizable and we will develop each WV DHHR facility's own plan in coordination with each facility and based on their specific needs. Training will be provided on-site at each facility and refresher training will be available upon request at any point during the contract period.

1.2.17 Vendor shall provide the facilities with all supplies and materials necessary of the

collection and transport of specimen for testing. This includes, but is not limited to: vaccutainers, tubes, needles, preservatives, 24 urine containers, cytology and histology containers with preservatives, slides, fixatives, plastic transport bags, centrifuges, and a directory for all services offered.

At no additional charge, all supplies necessary for the proper collection, processing, handling, and transport of specimens to be tested by Quest Diagnostics will be provided.

Supplies will be provided in line with our existing policies and procedures. Our Directory of Services includes a comprehensive Specimen Collection section outlining our policies. The Directory may be accessed online at <a href="https://www.nicholsinstitute.com">www.nicholsinstitute.com</a> and is also available in hard copy upon request.

1.2.18 Vendor shall provide microbiology culture results in accordance with the applicable standards for the specimen. Routine cultures with positive results shall have preliminary reports prepared within 24 hours, followed by a report within 48 hours, and a final report within 72 hours of collection of the specimen at the facility. Vendor shall telephone positive culture reports to the facility within one hour of receipt of results.

Preliminary microbiology culture result reports are available when ordered specifically and generally such reports can be provided within 24 hours after accessioning in our laboratory. Positive culture reports will be telephoned to the ordering facility in line with the Critical Values policy that has been provided as Attachment 4.

Turnaround time for all microbiology tests and all tests associated with this RFQ varies and has been provided with our price quote. Turnaround time is measured from time of accessioning in the performing laboratory to time of final result report and is based on test setup days and times.

1.2.19 Vendor shall provide general routine chemistries no later than 24 hours after collection of specimens at the facilities.

## Turnaround Time

As stated above, turnaround time for all tests associated with this RFQ varies and has been provided with our price quote. Turnaround time is measured from time of accessioning in the performing laboratory to time of final result report and is based on test setup days and times.

### Critical Values

Critical values will be called to the ordering facility consistent with our established Critical/Priority values policy (please see Attachment 4).

1.2.20 After collection of specimens, vendor shall provide turnaround time for Cytology results within five (5) days and Histology within four days (4) unless further study or staining is required.

## Exceptions to prescribed turnaround times are as follows:

Cytology results turnaround time:

Suspicious, abnormal, unusual specimens or those submitted with insufficient information may require a longer turnaround time; however, in the case of such occurrences the facility must be notified.

Surgical pathology turnaround time:

Depending on the complexity of diagnosis and case load, surgical pathology results may require a longer turnaround time; however, in the case of such occurrences the facility must be notified. A preliminary diagnosis shall be made available by the vendor via telephone or computer printer, with a signed report to follow.

As stated above, turnaround time for all tests associated with this RFQ varies and has been provided with our price quote. Turnaround time is measured from time of accessioning in the performing laboratory to time of final result report and is based on test setup days and times.

1.2.21 Vendor shall not sub-contract more than 1% (one percent) of the types of tests to be processed. The Vendor will be the Subagent to the Bureau and will be wholly responsible for all reference lab activities.

Quest Diagnostics can perform 100% of the testing associated with this RFQ within our national network of laboratories.

1.2.22 A list of the type and estimated quantity of tests, profiles, screens and cultures required by the facilities are attached as Exhibit A. This exhibit represents the most commonly required and/or requested tests and will be used for evaluation purposes.

A price quote has been provided.

1.2.23 This will be an open end contract. Quantities listed are estimates only. Actual amounts and test types will vary depending on the needs of the facilities whether those needs are greater or less than the quantities listed.

Quest Diagnostics agrees to a contract term and type as specified on the RFQ sheets provided by the West Virginia Department of Administration Purchasing Division with this bid.

2. Method of Evaluation:

The contract will be awarded to a single vendor with the **lowest grand total** cost for providing the services listed in Exhibits A, B, & C and that meets all mandatory requirements. All bids should be inclusive.

Quest Diagnostics understands that the intent is to award to the vendor meeting all mandatory requirements with the lowest grand total cost for the services listed in Exhibits A, B, & C.

The prices provided are inclusive of the services described herein. If additional or enhanced services are required (ex. STAT pickups that fall outside of existing logistics), additional fees may apply. Such fees will be negotiated as your services requirements change.

## Payment:

The vendor shall submit monthly invoices, in arrears, on a monthly basis, to the Facility at the address on the face of the purchase order labeled "Invoice To" pursuant to the terms of the contract. Payment will be made in arrears, upon completion of delivery, installation, and in-service training. State law forbids payment of invoices prior to receipt of goods or services.

Charges will accumulate daily as testing is completed and invoices will be issued monthly to the appropriate facility. Payment terms will be net 30 days and the completion of "delivery" and "installation" is not applicable. The obligation to pay for services rendered prior to the termination of the agreement shall survive termination of the agreement.

In addition, it is our expectation that Quest Diagnostics is provided with all information that we believe is required to properly invoice and receive payment for laboratory testing services. It will be the responsibility of the ordering facility to ensure that all necessary information accompanies each specimen submitted for testing.

## 4. Insurance Requirements:

The vendor, as an independent contractor, is solely liable for the acts and omissions of its employees and agents. The vendor shall maintain and furnish proof of coverage of liability insurance for loss, damage, or injury (including death) of third parties arising from acts or omissions on the part of the vendor, its agents and employees in the following amounts:

- 1) For Bodily Injury (including death): Minimum amount of \$1,000,000 per occurrence.
- 2) For property damage and professional liability: Minimum amount of \$1,000,000 per occurrence.

Quest Diagnostics is self-insured to the first \$5 million of each and every general and professional liability claim. Ample excess insurance is provided by Lexington Insurance Company.

A certificate of insurance has been provided as Exhibit 5 and Quest Diagnostics agrees to maintain insurance as specified in that document.

# WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES

# BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES

# Reference Laboratory Services OPEN END CONTRACT - BHS12155 Bid Sheet

	BHS12155		Column A	Column B	Column C
	EXHIBIT A - Bid Sheet				
	Item Description (Test)	CPT Codes	Estimated Annual Volume of Tests	Cost Per Test	Total (A x B)
	ADRENOCORTICOTROPIC HORMONE				
1	(ACTH)	82024	120	\$60.29	\$7,234.50
	AEROBIC BACTERIAL CULTURE GEN.	87070	210	\$20.13	\$4,226.25
	AEROBIC IDENTIFICATION	87077	30	\$21.53	\$645.75
	a-FETOPROTEIN (AFP)	82105	65	\$24.68	\$1,603.88
	ALANINE AMINOTRANSFERASE (ALT)	84460	160	\$0.88	\$140.80
	ALBUMIN	82040	250	\$5.51	\$1,378.13
	AMMONIA	82140	70	\$21.09	\$1,476.13
	AMYLASE	82150	65	\$8.58	\$557.38
	ANAEROBIC CULTURE	87075	145	\$23.10	\$3,349.50
	ANTINUCLEAR ANTIBODIES (ANA)	86038	80	\$5.70	\$456.00
	ANTISTREPTOLYSIN O ANTIBODIES (ASO)	86060	20	\$10.85	\$217.00
	ASPARTATE AMINOTRANFERASE (AST)	84450	100	\$0.88	\$88.00
	BASIC METABOLIC PANEL	80048	435	\$1.21	\$524.44
	BILIRUBIN DIRECT	82248	10	\$5.51	\$55.13
	BILIRUBIN TOTAL	82247	10	\$0.88	\$8.80
	B-TYPE NATIURETIC PEPTIDE (BNP)	83880	15		\$2,227.50
	C4-BINDING PROTEIN	83520	150	,	\$15,750.00
	CALCITROL (VITAMIN D 1, 25 DIHYDROXY)	82652	300	\$20.00	\$6,000.00
	CALCIUM	82310	60	\$5.51	\$330.75
	CALCIUM IONIZED	82230	10	\$17.50	\$175.00
	CARBAMAZEPINE	80156	100	\$100.00	\$10,000.00
	CD 4 HELPER T-LYMPH	86360	10	\$49.18	\$491.75
	CHLAMYDIA by GENPROBE	87490	320	\$28.79	\$9,212.00
	CHOLESTEROL	82465	10	\$5.69	\$56.88
	CLOSTRIDIUM DIFFICILE TOXINS	87324	80	\$30.36	\$2,429.00
	CLOZAPINE	80154	20	\$90.00	\$1,800.00
	COMPLETE BLOOD COUNT (CBC) WITH DIF	85025	2850	\$1.25	\$3,562.50
	C-PEPTIDE	84681	25	\$29.14	\$728.44
	CREATINE	82565	250	\$12.16	\$3,040.63
	CREATINE KINASE (CK) MB	82553	10	\$22.75	\$227.50
	CREATINE KINASE (CK) TOTAL	82550	110		\$1,309.00
	CULTURE, BLOOD	87040	350		\$7,258.13
	CULTURE, STOOL	87427	25	\$20.13	\$503.13
	CULTURE, URINE	87086	650	\$4.00	\$2,600.00
	DIGOXIN	80162	120	\$17.94	\$2,152.50
	DRUG SCREEN CONFIRMATION	00102	120	ψιι.υτ	Ψ2,102.00
	(INDIVIDUAL DRUGS)	80102	950	\$39.81	\$37,821.88
	DRUG SCREEN URINE	80101 X 10	1350	\$37.00	\$49,950.00
	ELECTROLYTES	80051	275	\$5.86	\$1,612.19
	ETHANOL, ALCOHOL	82055	10		\$346.50
7(0)					

A1	FERRITIN	82728	65	\$7.00	\$455.00
	FOLATE	2746	290	\$5.00	\$1,450.00
	FOLATE RBC	82747	125	\$104.00	\$13,000.00
1 40	FOLLICULAR STIMULATING HORMONE	02141	120	φ104.00	\$13,000.00
11	(FSH)	83001	20	\$26.43	\$528.50
	GLUCOSE	82947	170	\$7.61	\$1,294.13
	CLUCOSE TOLERANCE TEST	82952	15	\$6.21	\$93.19
			1200		
	CLUTAMYLTRANSERASE, GAMMA (GGT)	82977		\$5.51 \$48.25	\$6,615.00
	CYNECOLOGIC PAP SMEAR	88175	230	•	\$11,097.50
	CYNECOLOGIC PAP SMEAR THIN PREP HALOPERIDOL	88147	50	\$48.25	\$2,412.50
		80173	15 30	\$33.95	\$509.25
	HDL CHOLESTEROL	83718		\$10.06	\$301.88
	HELICOBACTER PYLORI ANTIBODIES	86677	15	\$115.50	\$1,732.50
	HEMATOCRIT	85014	25	\$3.68	\$91.88
	HEMOGLOBIN (11D) A40	85018	25	\$3.68	\$91.88
	HEMOGLOBIN (HB) A1C	83036	950	\$7.00	\$6,650.00
	HEATIC PANEL (LIVER)	80076	350	\$1.15	\$403.48
	HEPATITIS A IGM	86709	250	\$6.00	\$1,500.00
1	HEPATITIS B CORE AB IgG	86704	710	\$8.00	\$5,680.00
	HEPATITIS B CORE AB IgM	86705	250	\$6.00	\$1,500.00
	HEPATITIS B S AB	86076	220	\$6.00	\$1,320.00
	HEPATITIS B S AG	87340	1150	\$6.00	\$6,900.00
	HEPATITIS C AB	86803	620	\$6.00	\$3,720.00
	HEPATITIS C BY PCE	87521	10	\$221.00	\$2,210.00
	HEPATITIS C GENOTYPE	87902	10	\$410.00	\$4,100.00
65	HEPATITIS PROFILE, ACUTE	80074	450	\$25.00	\$11,250.00
66	HERPES CULTURE	87255	10	\$14.00	\$140.00
67	HERPES SIMPLEX VIRUS (HSV)	87273	35	\$21.79	\$762.56
68	HUMAN CHORIONIC GONADOTROPIN	84703	100	\$14.53	\$1,452.50
	HUMAN CHORIONIC GONADOTROPIN,				
	URINE	81025	15	\$7.26	\$108.94
70	HUMAN IMMUNODEFICIENCY VIRUS (HIV)	86701	150	\$7.25	\$1,087.50
	HUMAN IMMUNODEFICIENCY VIRUS RNA				
71	BY PCR	87536	30	\$295.00	\$8,850.00
72	INSULIN	83525	35	\$17.50	\$612.50
73	IRON	83540	1270	\$6.65	\$8,445.50
74	IRON BINDING CAPACITY (IBC)	83550	20	\$9.70	\$194.00
	LACTIC ACID DEHYDROGÈNASE (LD)	83615	1200	\$17.59	\$21,105.00
76	LAMOTRIGINE (LOMICTAL)	82491	10	\$40.16	\$401.63
	LEAD	83655	70	\$22.75	\$1,592.50
	LIPASE	83690	20	\$10.41	\$208.25
	LIPID PANEL	80061	1800	\$1.75	\$3,150.00
80	LITHIUM	80178	600	\$10.06	\$6,037.50
	LOW DENSITY LIPOPROTEIN (LDL)			,	. ,
	CHOLESTEROL	83721	35	\$18.38	\$643.13
-	LUTEINIZING HORMONE (LH)	83002	15	\$26.43	\$396.38
	MAGNESIUM	83735	150	\$8.58	\$1,286.25
	METABOLIC PANEL COMPREHENSIVE	80053	1900	\$1.50	\$2,842.40
	MICROALBUMIN URINE	82043	20	\$23.36	\$467.25
	MONONUCLEOUS	86309	30	\$7.26	\$217.88
	MUMPS	86735	30	\$29.40	\$882.00
	MYCOBACTERIUM (REFLEX @ ADD. COST)	87186	10	\$56.35	\$563.50
	NEISSERIA GONORRHOEAE, GC by	37 100	10	400,00	<del>+300,00</del>
	GENPROBE	87590	310	\$17.76	\$5,506.38
	OVA & PARASITE	87177	20	\$44.63	\$892.50
	PARATHYROID HORMINE, (PTH) INTACT	83970	115	\$53.64	\$6,168.31
91	CARACTERIOR TO TOTAL TELEPORT (1911) RYANGE	00010	113	ψυυ.υτ	ψυ, ιυυ.υ ι

92 PARTIAL THROMBOPLASTIN TIME (PTT)	85730	150	\$8.23	\$1,233.75
93 PHENOBARBITAL	80184	100	\$17.59	\$1,758.75
94 PHENYTOIN DILANTIN	80185	350	\$24.15	\$8,452.50
95 PHOSPHOROUS	84100	1300	\$5.51	\$7,166.25
96 POTASSIUM	84132	50	\$5.51	\$275.63
97 PREALBUMIN	84134	150	\$24.24	\$3,635.63
98 PRIMIDONE, MYSOLINE	80188	10	\$21.61	\$216.13
99 PROLACTIN	84146	50	\$9.00	\$450.00
100 PROSTATE SPECIFIC ANTIGEN (PSA)	84153	100	\$41.30	\$4,130.00
101 PROTEIN ELECTROPHORESIS	84155	15	\$11.29	\$169.31
102 PROTHROMBIN TIME (PT)	85610	850	\$8.31	\$7,065.63
103 RAPID PLASMA REAGIN (RPR)	86592	330	\$5.50	\$1,815.00
104 RENAL FUNCTION PANEL	80069	100	\$7.09	\$708.75
105 RETICULOCYTE	85044	20	\$4.00	\$80.00
106 RHEUMATOID FACTOR (RF)	86430	15	\$14.00	\$210.00
107 RUBELLA	86762	30	\$8.00	\$240.00
108 RUBEOLA	86765	30	\$33.25	\$997.50
109 SEDIMENTATION RATE (ESR)	85651	30	\$7.09	\$212.63
110 SODIUM	84295	25	\$5.51	\$137.81
111 TESTOSTERONE, TOTAL	84403	50	\$7.00	\$350.00
112 THEOPHYLLINE	80198	60	\$20.13	\$1,207.50
113 THYROID STIMULATING HORMONE (TSH)	84443	400	\$2.00	\$800.00
114 THYROXINE (T4)	84436	830	\$8.49	\$7,044.63
115 THYROIXINE (T4), FREE	84439	1300	\$7.20	\$9,360.00
116 TRIGLYCERIDES	84478	15	\$5.51	\$82.69
117 TRIIODOTHYRONINE (T3)	84480	860	\$31.50	\$27,090.00
118 TRIIODOTHYRONINE (T3) FREE	84481	70	\$55.65	\$3,895.50
119 TROPONIN	84484	10	\$104.75	\$1,047.50
120 UREA NITROGEN (BUN)	84520	240	\$5.51	\$1,323.00
121 URIC ACID	84550	1250	\$0.88	\$1,100.00
122 URINALYSIS	81000	1250	\$2.89	\$3,609.38
123 VALPROIC ACID	80164	1000	\$21.96	\$21,962.50
124 VARICELLA ZOSTER VIRUS	86787	100	\$7.50	\$750.00
125 VITAMIN B12	82607	400	\$22.93	\$9,170.00
126 VITAMIND D 25-HYDROXY	82306	75	\$20.00	\$1,500.00
		Total of Exhibi	t A - Bid Sheet	\$470,211.10

# Quest Diagnostics Nichols Institute - Chantilly, VA Pricing Evaluation and Proposal for West VA Dept. of Health and Human Resources - Charlestown, WV - May 2012

Chantilly		Chantilly	Vendor Vendor	Annual Proposed	Proposed	Proposed	Chantilly	Chantilly	Chantilly	Chantilly
Test Code NTC	NTCx	Procedure Name	Code Test Description	Volumo Specials	Quest Fees	Quest Fees Ext	CPT Code(s)	Setup/Shift	Report Available	Place of Service
2533 21 4550	1 211)	X ACTH, PLASMA	82024 ADRENOCORTICOTROPIC HORMONE (ACTH)	120	\$60.29	\$7,234.50	82024	Mo-Fr M	2 Days	Nichola Institute- Chantilly, VA
3381	341180	WOUND CULTURE X BACTERIAL IDENTIFICATION NON URINE ISOLATE	87070 AEROBIC BACTERIAL CULTURE GEN. 87077 AEROBIC IDENTIFICATION	210 30	\$20,13 \$21.53 \$24.68	\$4,228.25 \$645.75	87070-90 87077	Mo-Su M,A,N Mo-Su M,A,N	4 Days 7 Days	Nichols Institute- San Juan Capatrano Nichols Institute- Chantilly, VA
920 23 319	7 2377 8233	X ALPHA-FETOPROTEIN TUMORMARKER X ALANINE AMINOTRANS-FERASE (ALT)	82105 &-FETOPROTEIN (AFP) 84460 ALANINE AMINOTRANSFERASE (ALT)	65 160 *	\$24.68 \$0.88	\$1,603.88	82105 84460	Mo-Fr M Mo-Fr M A C N Sp M St M N	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
5890 55098	223)	X ALBUMIN X AMMONIA, (P)	82040 ALBUMIN 82140 AMMONIA	250	\$5.51	\$1,378.13	82040	Mo-Fr M,A,E,N Sa M Su M,N Mo-Fr M,A,E,N Sa M Su M,N	Next Day	Nichola institute- Chantily, VA
272 13126		IAMYLASE SERUM	82150 AMYLASE	70 65	\$21.09 \$8,58	\$1,476.13 \$557.38	82140 82150	Mo-Sa M,N Su N Mo-Sa M	Next Day Next Day	Nichols institute- Chantilly, VA Nichols institute- Chantilly, VA
13126 18167	4469)	X ANAEROBIC CULTURE AND MIC ANA, TITER AND PATTERN	87075 ANAEROBIC CULTURE 88038 ANTINUCLEAR ANTIBODIES (ANA)	145 50	\$23.10 \$5.70	\$3,349.50 \$456.00	6,707,567,205 86039	Mo-Su M.A.E.N	9 Days	Nichols institute- Chantilly, VA Nichols institute- Chantilly, VA
31 320	265)	X STREPTOLYSIN O ANTIBODY	86060 ANTISTREPTOLYSIN CANTIBODIES (ASO)	20	\$10.85	\$217.00	86060	Mo-Sa M Mo-Fr M.E.N Sa M Su N	Next Day Next Day	Nichols Institute- Chantilly, VA
11206	10165)	X ASPARTATE AMINOTRANS-FERASE (ASY) X BASIC METABOLIC PANELWIE OFR	64450 ASPARTATE AMINOTRANFERASE (AST) 60048 BASIC METABOLIC PANEL	100 435	\$0.88 \$1,21	\$88.00 \$524.44	84450 80048	Mo-Fr M,A,E,N Sa M Su M,N Mo-Fr,Su M,A,E,N Sa M,A,E	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
1888		X BILIRUBIN DIRECT	62248 BILIRUBIN DIRECT 52247 BILIRUBIN TOTAL	10	\$5.51 \$0.58	\$55.13 \$8.80	82248 82247	Mo-Fr M,A,E,N Sa M Su M,N Mo-Fr M,A,E,N Sa M Su M,N	Next Day Next Day	Nichols institute- Chantilly, VA Nichols Institute- Chantilly, VA
13121 15898	37386	X B-TYPE NATRIURETIC PEPTID(BNP) X C4 BINDING PROTEIN, SERUM	83880 B-TYPE NATIURETIC PEPTIDE (BNP) 83520 CA-BINDING PROTEIN	15 150	\$148.50	\$2,227.50	83660	Mo-Sa M	Next Day	Nichola Institute- Chantilly, VA
16558 1656	16558	VITAMIN D. 1,25-DIHYDROXYLCMSMS	82532: CALCITROL (VITAMIN D 1, 25 DIHYDROXY)	300	\$105.00 \$20.00	\$15,750.00 \$6,000.00	86329 62652	Tu A Mo-Sa E	4 Days 3 Days	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
425 30 67 30	3 303) 5 300)	X CALCIUM, TOTAL X CALCIUM, IONIZED	8230 CALCIUM 8230 CALCIUM IONIZED	60	\$6.51 \$17.50	\$330.75 \$175.00	62310 62330	Mo-Fr M,A,E,N Sa M Su M,N Mo-Su E	Next Day Next Day	Nichola Institute- Chentilly, VA Nichola Institute- Chentilly, VA
16949 1894 206831	el .	CARBAMAZEPINE, TOTALSERUMPLASMA LCMSMS THELPER (CD4)	80158; CARBAMAZEPINE	100	\$100.00	\$10,000.00	80156	i Mo-Fr M	2 Days	Nichole Institute- Chantilly, VA
2602	8502		85380 CD 4 HELPER T-LYMPH 87490 CHLAMYDIA by GENPROBE	10 320	\$49.18 \$28.79 \$6.69	\$491.75 \$9,212.00	66361 67490	Mo-Sa M,A Mo-Sa M	Next Day 2 Days	Nichole Institute- Chantilly, VA Nichole Institute- Chantilly, VA
80 600	334)	K CHOLESTEROL, TOTAL  CLOSTRIDIUM DIFFICILE TOXINS A&B	82465 CHOLESTEROL 87324 CLOSTRIDIUM DIFFICILE TOXINS	10 80	\$5.69 \$30,36	\$56.88 \$2,429.00	82465 67324	Mo-Fr M.A.E.N Sa M Su M.N Mo-Su A.N	Next Day Next Day	Nichola Institute- Chantility, VA Nichola Institute- Chantility, VA
15687	17692	K CLOZAPINE(CLOZARIL)	80154 CLOZAPINE	20	\$90.00	\$1,600.00	82492	Mo-Fr M	Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
74 818 37	63997	K CBC WITH DIFFERENTIAL	85025 COMPLETE BLOOD COUNT (CBC) WITH DIFFERENTIAL 84881 C PEPTIDE	2850 * 25	\$1.25 \$29.14	\$3,582.50 \$728.44	85025 8486t	Mo-Sa M,A,E,N Mo-Fr E	Next Day Next Day	Nichols Institute- Chantilly, VA Nichols Institute- Chantilly, VA
96 37789 37	592X.370912	CREATINE CREATINE KINASE(CK) ISOEN	82585 CREATINE 82583 CREATINE KINASE (CK) MB	250 10 110	\$12.10	\$3,040.63 \$227.50	82540 82552	Mo-Fr A	Next Day	Nichola Institute- Chantilly, VA
99 37	\$ 3740	CREATINE KINASE, TOTAL	92550 CREATINE KINASE (CK) TOTAL 87040 CULTURE, BLOOD	110	\$22.75 \$11.90 \$20.74 \$20.13	\$1,309.00	82550	Mo-Fr,Su E Mo-Fr M,A,E,N Sn M Su M,N	2 Days Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
103 664	100192	BLOOD CULTURE COULTURE FECES	87840 CULTURE, BLOOD 87427 CULTURE, STOOL	350 25	\$20.74	\$1,309.00 \$7,258.13 \$503.13	87040 87045	Mo-Su M,A,E,N Mo-Su M.A.N	7 Days 4 Days	Nighola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
685 64	3950	K_CULTURE,URINE,ROUTINE	87086 CULTURE, URINE	650	\$4.00	\$2,600.00	87088 80162	Mo-Su M,A,E,N	3 Days	Nichols Institute- Chantilly, VA
13402		LOGONN COCAINE, CONFIRM BY GCMS, SERUM	80102 DRUG SCREEN CONFIRMATION (INDIVIDUAL DRUGS) 80102 DRUG SCREEN URINE	120 950	\$17,94 \$39.81	\$2,152.50 \$37,821.88 \$49,950.00	82520	Mo-Th A Fr,Sa E Mo-Su M	Next Day 3 Days	Nichols Institute- Chantilly, VA Nichols Institute- Chantilly, VA
18249	29423)	CDRUG ABUSE PANEL 10 CELECTROLYTE PANEL, SERUM	80101 X 10 DRUG SCREEN URINE 80051 ELECTROLYTES	1350 *	\$37.00 \$5.86	\$49,950.00	80101*10 80051	Mo-Sa M Mo-Fr,Su M,N Sa M	3 Days Next Day	Nichols institute- Chantilly, VA Nichols institute- Chantilly, VA
18246 132 455	2128)	CALCOHOL, ETHYL, QUAL	82055 ETMANOL, ALCOHOL	275 10	\$34.65	\$1,612.19 \$346.50	80101	Mo-Sa M	3 Days	Nichole Institute- Chantily, VA
859 45	4572	K FATTY ACIDS, FEGAL TOTAL K FERRITIN	82710 FECAL FAT 82728 FERRITIN	10 85 *	\$49.53 \$7.00	\$495.25 \$456.00	82710-90 82728	Mo-Th M Mo-Se M _i N Su N	5 Days Next Day	Nichola Institute- San Juan Capiatrano Nichola Institute- Chantilly, VA
265 466 14178	4667	FOLIC ACID	2746 FOLATE 82747 FOLATE RBC	290 * 125	\$5.00 \$104.00	\$1,450.00 \$13,000.00	82746 82747	Mo-Fr M,A,E,N S# M,N SU N Mo-Fr E	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
4942 470 148	470>	( FSH, SERUM	63001 FOLLICULAR STIMULATING HORMONE (FSH)	20	£26.43	\$528.50	83001	Mo-Fr M.A.E.N Sa M.N Su N	Next Day	Nichols Institute- Chantilly, VA
18042	1	GLUCOSE GLUCOSE TOLERANCE, 2 SPECIMENS	52952 CLUCOSE TOLERANCE TEST	170 18	\$7.61 \$6.21	\$1,294,13 \$93.19	82947 8,294,782,960	Mo-Fr M,A,E,N Sa M Su M,N Mo-Su M	Next Day Same Day	Nichols institute- Chantilly, VA Nichols Institute- Chantilly, VA
587	354550	( GAMMA GLUTAMYL TRANSFERASE (GGT)	62977 CLUTAMYLTRANSERASE, GAMMA (GGT) 68175 CYNECOLOGIC PAP SMEAR	1200 230	\$5.51 \$48.25	\$6,615.00 \$11,097.50	62977 88142	Mo-Fr M,A,E,N Sa M Su M,N Mo-Fr M	Next Day 5 Days	Nichole Institute- Chantilly, VA Nichole Institute- Chantilly, VA
5310 670 58-	35455)	THIN PREP, PAP SMEAR HALOPERIDOL	88147 CYNECOLOGIC PAP SMEAR THIN PREP 80173 HALOPERIDOL	50	\$46.25 \$33.95	\$2,412,50	88142	Mo-Fr M	5 Days	Nichola Institute- Chantilly, VA
964	608	HOL CHOLESTEROL	83716 HDL CHOLESTEROL 83716 HDL CHOLESTEROL 86877 HELICOBACTER PYLORI ANTIBODIES	30	\$10.08	\$509.25 \$301.88	80173-90 63718	Tu,Th,Su N Mo-Fr M,A,E,N Sa M Su M,N	4 Days Next Day	Nichola Institute- San Juan Capletrano Nichola Institute- Chantilty, VA
5705 157	203252	HELICOBACTER PYLORI ABIGG, A, M	65677; HELICOBACTER PYLORI ANTIBODIES 65014; HEMATOCRIT	15 25	\$115.50 \$3.68	\$1,732.50 \$91.88	66677*3 85014	Mo,We,Fr M Mo-Sa M,A,E,N	Next Day Next Day	Nichols Institute- Chantilly, VA Nichola Institute- Chantilly, VA
158	510>	( HEMOGLOBIN	65018 HEMOGLOBIN	25 25	\$3.68	\$91.88	65018	Mo-Sa M,A,E,N	Next Day	Nichola Institute- Chantilly, VA
25 490 11209	102562	GLYCOHEMOGLOBIN, H8A1C HEPATIC FUNCTION - 2000	B3036 HEMOGLOBIN (HB) A1C B0076: HEATIC PANEL (LIVER) B3709 HEPATITIS A IGM	950 * 350 *	\$7.00 \$1.15	\$6,650.00 \$403.48	83036 60076	Mo-Fr M, N Mo-Fr, Su M, N Se M	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
1003 512 813 501	5122	HEPATITIS A IGM HEPATITIS B CORE AS TOTAL	86709 HEPATITIS A 10M 86704 HEPATITIS B CORE AB 1gG	250 * 710 *	\$8.00	\$1,500.00 \$5,680.00	86709 86704	Mo-Fr M,E Sa M Mo-Sa M	Next Day Next Day	Nichole Institute- Chentilly, VA Nichole Institute- Chentilly, VA
2156 4844	3 4840>	CHEP B CORE AB (IGM)	86705 HEPATITIS B CORE AB IgM	250	\$8.00	\$1,500.00	66706	Mo-Sa M	Next Day	Nichola Institute- Chantilly, VA
718 408 453 498		HEPATITIS B SURFACE ANTIBODY, QUALITATIVE HEPATITIS B SURFACE AGWIREFLEX TO CONFIRM	86076 HEPATITIS B S AB 87340 HEPATITIS B S AG	220	\$8.00 \$6.00	\$1,320.00	86706 87340	Mo-Se M Mo-Sa M	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
3571 37273	8472)	MEPATITIS C VIRUS AB EIA	85803 HEPATITIS C AB 87521 HEPATITIS C BY PCE	650 .	\$8.00	\$3,720.00	96803 87521	Mo-Sa M	Next Day	Nichole Institute- Chantilly, VA
7400 37811	378112	HEPATITIS C GENOTYPING HEPATITIS PANEL ACUTE W/REFLEX TO CONFIRMATION	87902 HEPATITIS C GENOTYPE	10	\$221.00 \$410.00	\$2,210.00 \$4,100.00	87902	Mo-FrM Mo-FrM	3 Days Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
10306 10306 2725	26492	HEPATITIS PANEL, ACUTE W/REFLEX TO CONFIRMATION  HERPES SIMPLEX VIRUS CULTURE PROGRESSIVE	80074 HEPATITIS PROFILE, AGUTE 87265 HERPES GULTURE	450 °	\$25.00 \$14.00	\$11,250.00	86705, 86709, 86803, 87340 87255	Mo-Se M Mo-Su A	Next Day 2 Days	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
13697 6532	36363	( HSV 1 IGG, TYPE-SPECIFICAS (HERPESELECT (R)) K HUMAN CHORIONIC GONDAOTROPIN (HCG), SERUM	87273 HERPES SIMPLEX VIRUS (HSV) 84703 HUMAN CHORIONIC GONADOTROPIN	35 100	\$14.00 \$21.79 \$14.53	\$140.00 \$762.56	86095 84703	Mo-Sa M	Next Day	Nichola Institute- Chantilly, VA
235 394	3	CHORIONIC GONADOTROPIN, URINE, QUALITATIVE	81025 HUMAN CHORIONIC GONADOTROPIN, URINE	15	\$7.26	\$108.94	84703	Mo-Fr,Su M,N Sa M Mo-Su M,A,E,N	Next Day Next Day	Nichola institute- Chantilly, VA Nichola institute- Chantilly, VA
12047 19726 40085 40085	400852	CHORIONIC CONADOTROPIN, URINE, QUALITATIVE HIV ANTIBODY, HIV-1/2, EIA, W/REFLEXES VVIRAL RNA ONT REAL TIME PCR	8701 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 87536 HUMAN IMMUNODEFICIENCY VIRUS RNA SY PCR	150	\$7.25 \$295.00	\$1,087.50	86703 67538	Mo-Sa M Mo-Sa M	Next Day Next Day	Nichola institute- Chantilly, VA Nichola institute- Chantilly, VA
15679 561 174 571	: 501X	INSULIN INSULIN IRON, TOTAL	83525 INSULIN 83540 IRON	35 1270	\$17.50 \$8.65	\$8,650.00 \$612.50 \$8,445.60	83525 83540	Mo-Fr E Mo-Fr M,A,E,N Se M Su M,N	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
175 757	75732	( IRON AND IRON-BINDING CAPACITY	83550 IRON BINDING CAPACITY (ISC)	20 -	\$9.70	\$194.00	8,354,083,550	Mo-Th,Su M,N Fr M,E,N Sa M	Next Day	Nighols Institute- Chantilly, VA Nichols Institute- Chantilly, VA
3843 585 5896 22060	585X	LACTIC ACID, PLASMA	83815 LACTIC ACID DEHYDROGENASE (LD) 82401 LAMOTRIGINE (LOMICTAL)	1200 10	\$17.59 \$40.18	\$21,105.00 \$401.63	63806 Anzeig	Mo-Fr M,A,E,N Su N Mo-Fr M	Next Day 2 Days	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
900152 590 157 600		LEAD, BLOOD LIPASE, SERUM	83665 LEAO 63600 LIPASE	70	\$22.75 \$10.41	\$1,592.50 \$268,25	63655 83690	Mo-Sa M	Next Day Next Day	Nighols Institute- Chantilly, VA
1040	76DD>	LIPID PANEL	60061 LIPID PANEL	20 1800 *	\$1.75	\$3,150.00	824,658,371,884,476	Mo-Su M,A,N Mo-Fr M,A,E,N Su M Su M,N	Need Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
466 613 6593	8 613) 829%	LITHRUM DIRECT LDL	80178 LITHIUM 83721: LOW DENSITY LIPOPROTEIN (LDL) CHOLESTEROL	600 35	\$10.06 \$18.38	\$6,037.50 \$643.13	80178 83721-59	Mo-Sa N Mo-Fr M,A,E,N Sa M Su M,N	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
4722 615	615>	LH, SERUM	50002; LUTEINIZING HORMONE (LH)	15	526.43	\$396.38	83002	Mo-FrM,A,E,N Sa M,N Su N	Next Day	Nighola Institute- Chantilly, VA
195 11207	102312	( MAGNESIUM K COMP. METABOLIC PANELW/E GFR	53735 MAGNESIUM 50053 METABOLIC PANEL COMPREHENSIVE	150 1900 •	\$8.58 \$1.50	\$1,265.25 \$2,642.40	63735 80053	Mo-Fr M,A,E,N Sa M Su M,N Mo-Fr,Su M,A,E,N Sa M,A,E	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
26877 17674 419 65-	si	MICROALBUMIN, RANDOM URINE	82043 MICROALBUMIN URINE 86309 MONONUCLEOUS	20 30	\$23.38 \$7.26	\$467.25 \$217.88	82043 86308	Mo-Se M,N Su N Mo-Sa M,A,N	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
2084 8624	1 86249	MUMPS ARIGO FIA	88735 MUMPS	30	\$29.40	\$862.00	86735	Mo-Fr M	Next Day	Nichola institute- Chantilly, VA
19079 2668	8501X	ANTIMICROBIAL SUSCEPTIBILITY, AFB, RAPID GROWER N GONORRHOEAE DNA PROBEENDOCK OR MALE URETHRAL	87188 MYCOBACTERIUM (REFLEX & AGO. COST) 87590 NEISSERIA GONORRHOEAE, GC by GENPROBE	10 310	\$56.35 \$17.76	\$563.50 \$5,508.38	87186 87590	Mo,Th M Mo-Sa M	14 Days 2 Days	Focus Nichols Institute- Chantilly, VA
17468 8597 35202	1748X	OVA AND PARASITES WITHGIARDIA ANTIGEN	87177 OVA 8 PARASITE 83970 PARATHYROID HORMINE (PTH) INTACT	20	\$44.63	\$892.50	871,778,720,687,329 83970	Mo-FrA,N	5 Days	Nichols Institute- Chantilly, VA
2133	7633	ACTIVATED PARTIAL THROMBOPLASTIN TIME	85730 PARTIAL THROMBOPLASTIN TIME (PTT)	150	\$53.64 \$8.23	\$8,168.31 \$1,233.75	85730	Mo-Fr M Mo-Fr M	Next Day Next Day	Nichols Institute- Chantilly, VA Nichols Institute- Chantilly, VA
214 58 713	7133	PHENOBARBITAL PHENYTOIN	80184 PHENOBARBITAL 80185 PHENYTOIN DILANTIN	100 350	\$17.59 \$24.15	\$1,758.75 \$8,452.50	80184 80185	Mo-Th A Fr,Sq E Mo-Th A Fr,Sq E	Next Day Next Day	Nichola Institute- Chantilly, VA Nichola Institute- Chantilly, VA
2222 718	7182	PHOSPHATE (AS PHOSPHORUS)	84100 PHOSPHOROUS	1300	\$5.51	\$7,166.25	84100	Mo-Fr M.A.E.N Sa M Su M.A.N	Next Day	Nichols Institute- Chantilly, VA
231 730 1845	(33)	CPOTASSIUM CTRANSTHYRETIN	84132 POTASSIUM 84134 PREALBUMIN	50 150	\$5.51 \$24.24	\$275.63 \$3,635.63	84132 84134	Mo-Fr M.A.N Sa M Su M.N Mo-Sa A	Next Day Next Day	Nichols Institute- Chantilly, VA Nichols Institute- Chantilly, VA

## Quest Diagnostics Nichols Institute - Chantilly, VA Pricing Evaluation and Proposal for West VA Dept. of Health and Human Resources - Charlestown, WV - May 2012

nantilly	Chantilly	Vendor	Vendor	Annual Propos	Proposed	Proposed	Chantilly	Chantilly	Chantilly	Chantilly
ode NTC NTCX	Procedure Name	Code	Test Description	Volume Specia	s Quest Fees	Quest Fees Ext	CPT Code(s)	Satup/Shift	Report Available	Place of Service
Spring 2000 (1900)				50 00 0	rigal (marketikasib) r		8,018,480,188	504 (32) (.15G) (1863) (083) (1667 (1647 (1647)	Next Day	Nichola Institute- Chantilly, V
	X PRIMIDONE (MYSOLINE(R))	80188 PRIMIDO			\$21.61	\$218.13	8,018,480,188 84148	Mo-Sa M Mo-Su M.A.E.N	Next Day	Nichola Institute- Chantilly, V
	X PROLACTIN (PRL)	84146 PROLACT		50	\$9.00 \$41,30	\$450.00 \$4,130.00	84153	Mo-Fr M.A.E.N Sa M Su N	Next Day	Nichols Institute- Chantilly, V
	X PROSTATE SPECIFIC ANTIGENTOTAL		E SPECIFIC ANTIGEN (PSA)	100	\$11,29	\$159,31	8,415,584,185	Mo-Sg A	Next Day	Nichols Institute-Chantilly, V
	X PROTEIN ELECT. & TOTAL SERUM		ELECTROPHORESIS	15	\$8.31	\$7,065.63	85810	Mo-Sa N	Next Day	Nichola Institute- Chantilly, V
0134 8847	PROTHROMBIN TIME W/INR(S/A 241)	85610 PROTHR		650 330			86592	Mo-Su M.N	Next Day	Nichols Institute- Chantilly, \
	X RPR(MONITOR) W/RFLX TITER		ASMA REAGIN (RPR)	100	\$5.50 \$7.09	\$1,815.00 \$708.75	60069	Mo-Fr.Su M.A.E.N Se M.A.E.	Next Day	Nichols Institute- Chantilly, V
	X RENAL FUNCTION PANELW/EGFR	80089 RENAL P			\$4.00	\$80.00	85045	Mo-Se M.A.E.N	Next Day	Nichols Institute- Chantily.
	X RETICULOCYTE COUNT	85044 RETICUL		20	\$14.00	\$210.00	83520	Tu,Th M	Next Day	Nichols Institute- Charbily, V
	IX RHEUMATOID FACTOR (IGG)		TOID FACTOR (RF)	15	\$8.00	\$240.00	86762	Mo-Sa M	Next Day	Nichols Institute- Chantily,
	X RUBELLA IMMUNE STATUS	86762 RUBELLA				\$997.50	86765	Mo-Fr M	Next Day	Nichols Institute- Chantily,
	IX MEASLES IGG AB (RUBEOLA)	88765 RUBEOL	\	30	\$33.25 \$7.09	\$212.63	85651	Mo-Sa M.A.E.N	Next Day	Nichols Institute- Chantilly.
	X SEDIMENTATION RATE, RBC		TATION RATE (ESR)	25	35.51	\$137.81	84295	Mo-Fr M.A.E.N Sa M Su M.N	Next Day	Nichola Institute- Chantilly,
	X SODIUM	84295 SODIUM		- So -	\$7.00	\$350.00	84403	Mo-Fr E	2 Days	Nichola Institute- Chantilly,
	X TESTOSTERONE, TOTALLC/MS/MS	84403 TESTOS		50	\$20.13	\$1,207.50	80198	Mo-Th A Fr.Se E	Next Onv	Nichola Institute- Chantilly,
631 871	X THEOPHYLLINE	80198 THEOPH		400 *	\$2,00	\$800.00	84443	Mo-Fr M.A.E.N Sa M.N Su N	Next Day	Nichola Institute- Chantilly.
6229 899 89	IX TSH IX T-4 (THYROXINE), TOTAL		STIMULATING HORMONE (TSH)	830	\$8.49	\$7,044,63	84436	Mo-Fr.Su M.N Sa M	Next Day	Nichols Institute- Chantilly,
634 867 85	X T-4 (THYROXINE), TOTAL	64436 THYROX			\$7,20	\$9,360.00	64430	Mo-Sa M.N Su N	Next Day	Nichola Institute- Chantilly,
	IX. T4, FREE NON-DIALYSIS	84439 THYROIX		1300	\$5.51	\$82.69	84478	Mo-Fr M.A.E.N Sa M Su M.N	Next Day	Nichols Institute- Chantilly,
	X TRIGLYCERIDES	84478 TRIGLYC		850	\$31.50	\$27,090.00	64460	Mo-Su M.A.E.N	Next Day	Nichols Institute- Chantilly,
	X T3, TOTAL		THYRONINE (T3)	70	\$55.65	\$3,895.50	64481	Mo-Sa M.N	Next Day	Nighors Institute- Chantilly.
	X T3, FREE		HYRONINE (T3) FREE	10	\$104.75	\$1,047.50	84484	Mo-Su M.A.E.N	Next Day	Nichols Institute- Chantily,
	X TROPONIN I	84484 TROPON			\$5.51	\$1,323.00	84620	Mo-Fr M.A.E.N Sa M Su M.N	Next Day	Nichota Institute- Chantily,
	X UREA NITROGEN (BUN)	84520 UREA NI		240 1250	\$0.88	\$1,100.00	84550	Mo-Fr M.A.E.N Sa M Su M.N	Next Day	Nichols Institute- Chantily,
	X URIC ACID	84550 URIC AC				\$3,609.38	81003	Mo-Su A.N	Next Day	Nichols institute Chantily,
903 712 91	URINALYSIS, DIP STICK ONLY	81000 URINALY		1250	\$2,89 \$21,96	\$21,962.50	80164	Mo-Th A Fr.Sa E	Next Day	Nichols institute- Charbliv.
	X VALPROIC ACID	80164 VALPRO		1000		\$750.00	86787	Mo-Fr M	Next Day	Nichols Institute- Chantilly,
2306 4439 443	X VARICELLA-ZOSTER VIRUSIGG ANTIBODY	86787 VARICEL	A ZOSTER VIRUS	100	\$7.50					
264 927 92	X VITAMIN B12	82607 VITAMIN		400	\$22.93	\$9,170.00	82607	Mo-Sa M, N Su N	Next Day	Nichola Institute- Chantilly, 1
7306 17306 1730	X VITAMIN D.25-HYDROXY, LCMSMS	82306 VITAMINI	D 25-HYDROXY	75 *	\$20.00	\$1,500.00	82306	Mo-Fr E	2 Days	Nichols institute- Chantilly, \
			Annualized Yotals	30,006		\$470,211.10				
						ļ			-	
	special priced test. All other descountable tests are discounted a	A SEE of Count Donnation M	abala Padhi dala iki San Sahadi ik				12111			

In the event any reference laboratory, to which Quest Diagnositios Nichols Institute refers testing, increases its charges to Quest Diagnositios Nichols Institute at any time during the Initial Term or any Renewal Term of this Agreement, Quest Diagnositios Nichols Institute testing in creases its charges to Quest Diagnositios Nichols Institute at any time during the Initial Term or any Renewal Term of this Agreement, Quest Diagnositios Nichols Institute testing in creases its charges to Quest Diagnositios Nichols Institute at any time during the Initial Term or any Renewal Term of this Agreement, Quest Diagnositios Nichols Institute testing in creases its charges to Quest Diagnositios Nichols Institute at any time during the Initial Term or any Renewal Term of this Agreement, Quest Diagnositios Nichols Institute testing in creases its charges to Quest Diagnositios Nichols Institute at any time during the Initial Term or any Renewal Term of this Agreement, Quest Diagnositios Nichols Institute testing in create at any time during the Initial Term or any Renewal Term or an

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Reflex teating, if performed, is an additional charge.			 
legree with all pricing and terms listed above.	Microsoft Control of C		
West Virginia Dept. of Health and Human Resources (Representative) - Print Name			
West Virginia Dept. of Health and Human Resources (Representative) - Signature	Date		
Quest Diagnostics (Sales Representative) - Signature	Date		

# LABORATORY SERVICES AGREEMENT (Hospital)

THIS AGREEMENT, effective on the 7th day of May, 2012 ("Effective Date"), is by and between Quest Diagnostics Nichols Institute, Inc. ("Quest Diagnostics") and West Virginia Department of Health and Human Resources ("Hospital"). Hospital and Quest Diagnostics agree as follows:

## 1. SERVICES

- 1.1 Quest Diagnostics will provide laboratory testing services and related ancillary services of the type set forth on Attachment 1 ("Laboratory Services") to Hospital, including:
- the technical and professional component of anatomic and surgical pathology services
- clinical diagnostic laboratory testing, including analyses in the areas of clinical chemistry, hematology, serology, microbiology, cytogenetics, immunology, endocrinology, toxicology, histology, virology and cytology
- certain specimen collection supplies subject to their use solely by the Hospital for the collection of specimens to be tested by Quest Diagnostics
- courier services to pick up specimens from the Hospital
- reports back to the Hospital either via courier or in an electronic format

#### 1.2 Hospital agrees that:

- Chain-of- custody testing is excluded from this Agreement
- All Laboratory Services will be ordered by persons who are authorized under state and/or federal law to order laboratory tests.
- It will utilize an appropriate container for each specimen and provide adequate quantity, and ensure that specimens are properly processed, and are properly packaged for transport.
- Quest Diagnostics is not required to provide or arrange for laboratory testing services that are not listed on Attachment 1.
- It shall not submit to Quest Diagnostics any Proficiency Testing ("PT") samples, which Hospital receives for
  testing. If any PT samples are sent to Quest Diagnostics by Hospital Quest Diagnostics will comply with the
  applicable Clinical Laboratory Improvement Amendments of 1988 as amended ("CLIA") codified at 42 C.F.R.
  section 493.801(b)(4) related to receipt of such PT samples and shall be entitled to recover all costs and
  expenses that it incurs related to handling such incidents.

### 2. <u>COMPENSATION/BILLING</u>

- 2.1 Quest Diagnostics shall bill Hospital and Hospital shall pay Quest Diagnostics for all Laboratory Services at the fees set forth on Attachment 1 or, to the extent Hospital orders a Laboratory Service not listed on Attachment 1, Quest Diagnostics may, but shall not be required to, perform such testing and Quest Diagnostics may bill and Hospital shall pay Quest Diagnostics' list price until the parties mutually agree upon a negotiated fee for such testing.
- 2.2 The pricing provided in this Agreement is based upon Quest Diagnostics' understanding that the Hospital will send an anticipated volume of account billed testing so that Quest Diagnostics may factor economies of scale into its pricing. Hospital represents that it will on an annual basis utilize Quest Diagnostics for at least 80% of Hospital's total reference Laboratory Services which are directly billed to the Hospital. Hospital agrees that it will annually certify and provide written notice to Quest Diagnostics of satisfaction of this requirement, including by providing the calculation and supporting detail. Laboratory Services which are billed under Appendix A shall not be included in the amount of total laboratory services or the amount of services performed by Quest Diagnostics for purposes of determining compliance with this provision. In the event that Hospital is unable or unwilling to certify as to its satisfaction with this requirement, the rates set forth on Attachment 1 shall automatically increase by 2%.

- 2.3 Under certain circumstances, Hospital may request that Quest Diagnostics bill a third party payor for Laboratory Services. To the extent Hospital makes such a request from Quest Diagnostics the provisions of **Appendix A** shall apply without further action of the parties.
- 2.4 Except as may otherwise be provided in this Agreement, Hospital agrees to pay Quest Diagnostics by payment of check, certified money order or electronic wire transfer or other form of payment method approved by Quest Diagnostics, within thirty (30) days of the date of each Quest Diagnostics invoice for Laboratory Services, after which any undisputed unpaid invoice amounts shall be overdue. Quest Diagnostics is unable to accept payment by credit card, debit card or any other instrument requiring the payment of service fees or other charges to a third party. In the event that Quest Diagnostics sends the account for collection and/or initiates litigation in order to collect overdue amounts, Hospital shall be liable for all costs and expenses of such collection and/or litigation, including reasonable attorney's fees, court costs and expenses, and interest on amounts outstanding at the lower of the rate of 1.25% per month or the maximum amount permissible under law.
- 2.5 Unless this Agreement is terminated earlier pursuant to Section 3, all pricing contained in this Agreement shall be in effect for one (1) year from the Effective Date. Thereafter, the fees payable hereunder shall increase effective on each anniversary date of the Effective Date of this Agreement by an amount equal to three (3%) percent.

## 3. TERM AND TERMINATION

- 3.1 The Initial term of this Agreement shall commence on the Effective Date and continue for a period of three (3) years ("Initial Term") unless earlier terminated in the manner set forth below. This Agreement shall be automatically renewed for one year periods after the Initial Term, unless earlier terminated as set forth below, or unless either party provides notice one hundred and twenty (120) days before the expiration of the Initial Term or each anniversary thereof.
- 3.2 This Agreement may be terminated by either party in the event of a material breach by the other party upon the giving of thirty (30) days written notice setting forth such breach. However, if such breach is cured or action to cure such breach is promptly initiated within such thirty (30) day period and diligently pursued to conclusion during this thirty (30) day period, then such notice will be deemed to be withdrawn.
- 3.3 Either party may, upon written notice to the other party, immediately terminate this Agreement upon the occurrence of any of the following events (i)The other party makes an assignment for the benefit of creditors; (ii) A petition in bankruptcy or any insolvency proceeding is filed by or against the other party and is not dismissed within thirty (30) days from the date of filing; or (iii) All or substantially all of the property of the other party is levied upon or sold in any judicial proceedings; or (iv) The other party is excluded from participating in any federally funded program; or (v) A loss of licensure by the other party that renders the other party unable to perform its obligations under this Agreement.
- 3.4 Upon termination of this Agreement, neither party shall have any further obligation with the exception of obligations accruing prior to the date of termination, such as payment for Laboratory Services rendered prior to the termination of this Agreement at the rates set forth in this Agreement, (ii) payment of Laboratory Services rendered after the termination of the Agreement shall be at Quest Diagnostics' billed charges, and (iii) obligations, promises or covenants contained in this Agreement that expressly survive the termination of this Agreement.
- 3.5 If any Authority creates, enforces, interprets and/or implements laws, rules, regulations, or otherwise takes a position (or threatens to do so), that Quest Diagnostics is required to extend the pricing under this Agreement to any third party including but not limited to Medicare, Medicaid or any other governmental program, Quest Diagnostics may (i) immediately terminate this Agreement, or (ii) notify Hospital of the occurrence of one of the foregoing events and increase the pricing under this Agreement to the pricing levels of any such governmental program, provided that if Hospital notifies Quest Diagnostics of an objection to such increase in prices within ten (10) days of Hospital's receipt of notice from Quest Diagnostics, this Agreement will terminate upon Quest Diagnostics receipt of Hospital's notice. For purposes of this section, "Authority" shall include, but is not limited to, any court, legislative or authority body, and/or any branch of state, federal or local government (e.g., the Office of

Inspector General, Department of Justice, Department of Health and Human Services, Centers for Medicare and Medicaid Services, and/or any state Medicaid agency Department of Health Care Services. Quest Diagnostics may likewise immediately terminate this Agreement if it, in its sole discretion, determines that any portion of this Agreement may or does violate any law, rule, regulation or governmental policy, or any interpretation of any law, rule, regulation or governmental policy.

## 4. COMPLIANCE WITH LAW.

Each of the parties represents and warrants to the other party that it will comply with all applicable laws, rules or regulations ("Applicable Laws") as they may be amended from time to time. Applicable Laws include, but are not limited to, the federal Physician Self-Referral Law, 42 U.S.C. 1395nn, and the regulations promulgated thereunder (together, the "Stark Law"), similar state physician self-referral laws and regulations (together with the Stark Law, the "Self-Referral Laws"), the federal Medicare/Medicaid Anti-kickback Law and regulations promulgated thereunder (the "Federal Anti-kickback Law") and similar state Anti-kickback laws and regulations (together with the Federal Anti-kickback Law, the "Anti-kickback Laws") and the data privacy and security requirements of Health Insurance Portability and Accountability Act of 1996 and regulations promulgated thereunder (HIPAA"). This paragraph will survive the termination or expiration of this Agreement to the extent that the Applicable Laws pertain to ongoing obligations of a party under this Agreement.

## 5. **CONFIDENTIALITY**

All terms of this Agreement (including without limitation the pricing provisions) and information or data relating to the business or operations of any party to this Agreement acquired by any other party hereto in connection with this Agreement shall be treated as strictly confidential by the receiving party, and shall not, unless otherwise required by Applicable Laws, be disclosed by the receiving party without the prior written permission of the party hereto to whom the information in question relates. This provision shall survive termination of this Agreement.

### 6. RECORDS

If any services to be provided hereunder are federally funded, or otherwise subject to the requirements of the Department of Health and Human Services (HHS), until the expiration of four (4) years after the furnishing of Laboratory Services pursuant to this Agreement, Quest Diagnostics shall, upon written request, make available to the Secretary of HHS, the Comptroller General, or any of their duly authorized representatives, this Agreement, and any books, documents and records that are necessary to certify the nature and extent of the costs incurred by Hospital under this Agreement. This provision will apply if the amount paid under this Agreement is \$10,000 or more over a twelve (12) month period. The availability of Quest Diagnostics' books, documents and records will at all times be subject to such criteria and procedures for seeking or obtaining access as may be promulgated by the Secretary of HHS in regulations, and other applicable laws. Quest Diagnostics' disclosure under this provision will not be construed as a waiver of any legal rights to which Quest Diagnostics or Hospital may be entitled under statute or regulation. If Quest Diagnostics performs any of its duties pursuant to this Agreement through a subcontract with a related organization with a value or cost of \$10,000 or more over a twelve (12) month period, then such subcontract shall include a provision that is substantially similar to the language set forth hereinabove.

## 7. <u>INSURANCE</u>

Quest Diagnostics and Hospital agree to maintain professional liability insurance in amounts adequate to cover their respective acts and omissions. The parties agree that such coverage shall be, at a minimum, \$1,000,000 per claim and \$3,000,000 aggregate and that the parties shall maintain such coverage (or "tail" coverage thereon) for a period of at least three (3) years after the termination of this Agreement. Each party agrees to furnish a current and valid Certificate of Insurance or other acceptable documentation evidencing its professional liability insurance coverage. Quest Diagnostics may provide the coverage required by this Agreement through alternative risk programs, such as self-insurance programs, so long as they are conducted in accordance with reasonable actuarial funding recommendations and remain fully funded in accordance with such actuarial recommendations throughout the term of this Agreement and any tail period. The provisions of this section shall survive termination of this Agreement.

### 8. <u>MISCELLANEOUS</u>

- 8.1 It is understood that Quest Diagnostics' services hereunder are to be rendered in the capacity of an independent contractor of Hospital. Neither party has authority to enter into contracts or assume any obligations for or on behalf of the other party or to make any warranties or representations for or on behalf of the other party.
- 8.2 Any notice required to be given hereunder will be deemed to have been served properly, if mailed by certified or registered mail, postage prepaid (or Federal Express or equivalent courier), properly addressed and posted in a United States depository to the respective parties at the addresses set forth underneath the signature of party or any alternative address provided by the party.
- 8.3 Each party represents and warrants that it has not been convicted of a crime related to healthcare or is not currently listed by a federal agency as debarred, excluded or otherwise ineligible for participation in federally funded programs (including, without limitation, federally funded healthcare programs, such as Medicare and Medicaid). Each party shall notify the other party within 5 days after it receives notice that the notifying party is an Excluded Provider.
- 8.4 This Agreement constitutes the entire Agreement between Quest Diagnostics and Hospital with respect to the subject matter hereof and supersedes any prior understandings or agreements. Notwithstanding the foregoing, if the Hospital is a member of a GPO with which Quest Diagnostics is under contract and the Facility has complied with all requirements under that GPO agreement to access the rates set forth and that GPO approved, the terms of the GPO Agreement shall supersede any provisions of this Agreement. No modification of this Agreement will have any force or effect unless such modification specifically indicates it is a modification of this Agreement, is in writing and signed by authorized representatives of both parties.
- 8.5 If any provision of this Agreement is determined to be illegal, invalid or unenforceable by a court of competent jurisdiction, the parties shall endeavor in good faith to negotiate legal, valid and enforceable substitute provisions that fulfill as closely as possible the original intents and purposes of the Agreement. The remaining portions of the Agreement not declared illegal, invalid, or unenforceable shall remain in full force and effect only if the essential terms and conditions of this Agreement for each party remain valid, binding and enforceable and the economic and legal substance of the transactions contemplated by the Agreement are materially preserved for each party.
- 8.6 This Agreement shall not be assigned, delegated, or transferred by either party without the written consent of the other party, which consent shall not be unreasonably withheld or delayed. Notwithstanding the foregoing, Quest Diagnostics may refer work to an affiliated testing facility or to subcontracted providers without prior written consent. In addition, Hospital acknowledges that certain testing may be performed and billed directly to Hospital by Quest Diagnostics affiliated testing laboratories. This Agreement is intended to inure only to the benefit of Quest Diagnostics and Hospital.
- 8.7 In no event shall either party or its respective officers, directors, employees, agents or affiliates be liable for any special, exemplary, incidental, consequential or punitive damages, whether in contract, warranty, tort, strict liability or otherwise. These limitations shall apply notwithstanding any failure of essential purpose of any limited remedy and shall survive termination of this Agreement.
- 8.8 No party to this Agreement shall be liable for failure to perform any duty or obligation that said party may have under the Agreement where such failure has been caused by any event, foreseen or unforeseen, outside the reasonable control of the party who had the duty to perform and that renders performance impossible or impracticable, including, but not limited to, acts of God, terrorist acts, fire, strike, inevitable accident, war, or any other event, like or unlike those listed above (collectively, "Force Majeure Event"), but only to the extent prevented by the Force Majeure Event. In the event that there is a shortage of supplies required for performing the Laboratory Services, suppliers increase costs of reagents or other supplies, or a license or other fee is required to be paid in connection with performing the services, Quest Diagnostics may increase the fees set forth in Attachment 1.

IN WITNESS WHEREOF, the parties hereto having authority to bind the respective party have set their hands the date and year first above written.

QUEST DIAGNOSTICS NICHOLS	INSTITUTE, INC	HOSPITAL: WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES Charleston, WV				
CHANTILLY, VA						
Ву:		Ву:				
Print Name:		Title:				
Title:						
Date:						
Notice Addresses:						
To Quest Diagnostics:	14225 Newbro Chantilly, VA 2					
Copy to:	Quest Diagnos 3 Giralda Farm Madison, NJ O ATTN: General	7071				
To Hospital:	State of West Health and Hu Charleston, W Attn: Roberta	man Services 350 Capitol St. V 25301				

### **APPENDIX A TO LABORATORY SERVICES AGREEMENT**

A. For purposes of this Agreement, including this Appendix A, each of the following is a "third party payor":

Medicare, Medicaid and commercial payors. For each test order submitted by Hospital for Laboratory Services to be performed by Quest Diagnostics, Hospital shall be responsible for informing Quest Diagnostics as to the status of the patient as an inpatient, outpatient or non-patient ("inpatient, outpatient and non-patient" have the definition as set forth in the applicable Medicare regulations) on each requisition. Hospital agrees to have a sufficient process in place to identify Medicare patients who fall under Medicare's "72-Hour" rule, and to notify Quest Diagnostics of these patients so as to not cause Quest Diagnostics to bill the Medicare program for work referred to Quest Diagnostics by Hospital. Hospital agrees to hold Quest Diagnostics harmless in the event of any action related to any claims submitted by Quest Diagnostics to third party payor.

- B. To the extent that Quest Diagnostics agrees to bill third party payors for Laboratory Services hereunder, Hospital shall be required to submit correct, complete and timely billing information. Hospital agrees to provide complete and accurate billing information to accompany the test order. Such information includes, without limitation, complete and accurate (1) patient demographic information, (2) insurance/Medicaid eligibility information, (3) diagnosis codes in the form of ICD-9 codes, and (4) any other required billing information. In the event that complete and accurate billing information is NOT timely provided, or if Quest Diagnostics is otherwise not permitted by law to bill the payor requested, the Hospital agrees that it shall be held directly responsible for payment.
- C. If Hospital requests that Quest Diagnostics bill any third party payor for Laboratory Services hereunder and Quest Diagnostics agrees to perform such third party billing, Quest Diagnostics will only bill a third-party payor in the following situations:

## For Clinical Laboratory Services:

Medicare-Non-patients Only

<u>Medicaid</u>-Outpatients and Non-patients (only where permitted or required by state law e.g. Direct Medicaid Bill states.)

Commercial Payer-Outpatients and Non-patients Only

## For Anatomic Pathology Technical Component Services:

<u>Medicare</u>- Inpatients and Outpatients only if Hospital qualifies as a "covered hospital" (i.e. "grandfathered")* per the current CMS guidance, and Non-patients;

Medicaid -Inpatients, Outpatients and Non-patients - only where permitted or required by state law

Commercial Payer-Inpatients, Outpatients and Non-patients - (except set forth in D below)

### For Anatomic Pathology Professional Component Services:

Medicare- Inpatients, Outpatients and Non-patients

Medicaid -Inpatients, Outpatients and Non-patients

Commercial Payer-Inpatients, Outpatients and Non-patients

*A Covered Hospital Attestation must be on file in the form attached hereto as **Attachment 2** if technical or global service will be billed to Medicare by Quest Diagnostics. If Hospital is not qualified under the "grandfathering" exception, it will be billed directly by Quest Diagnostics for the technical component of anatomic pathology.

In all other situations not noted in Appendix A, Quest Diagnostics must bill the Hospital directly for clinical laboratory and anatomic pathology services.

D. Hospital will not request that Quest Diagnostics bill directly any third-party payor for services that Hospital is responsible for billing or is otherwise paid as part of its arrangement with the third party payor, e.g., hospital capitated or bundled rate arrangements that include the technical component of anatomic pathology. If the Hospital submits a test order to Quest Diagnostics for the technical component only of an anatomic pathology service each such referral shall constitute a representation that Hospital does not receive any remuneration from such payor for the technical component.

- E. Quest Diagnostics will not bill third party payors for testing it does not perform under the Agreement (for example tests that are referenced to another laboratory, including without limitation a Quest Diagnostics center of excellence not specifically included as a provider under the Agreement). Charges for such testing shall be direct client billed only.
- F. In the event of any amendment or other change in any law, rule or regulation which would have the effect of preventing or prohibiting Quest Diagnostics from billing for technical component services rendered to or on behalf of Hospital Medicare patients, then such technical component services shall thereafter be billed by Quest Diagnostics to Hospital, and paid by Hospital to Quest Diagnostics, in accordance with the fee schedule set forth in Attachment 1, or in the absence of an applicable fee set forth in Attachment 1, at the rate of one hundred percent (100%) of the Medicare fee schedule rate in effect at the time the service is performed.

## **ATTACHMENT 1**

# TO LABORATORY SERVICES AGREEMENT BETWEEN QUEST DIAGNOSTICS NICHOLS INSTITUTE, INC. AND West Virginia Department of Health and Human Resources

PLEASE REFER TO EXCEL SPREADSHEET AS ATTACHMENT 1 – SIGNATURE REQUIRED

# ATTACHMENT 2 TO LABORATORY SERVICES AGREEMENT ATTESTATION STATEMENT

This Attestation Statement addresses the requirements of Program Transmittals AB-01-47 and B-01-50, Change Request 1781, regarding § 542 of the Benefits Improvement and Protection Act of 2000 and the Attestation Option for Submission Requirement for Clinical Laboratories Billing the Technical Component of Physician Pathology Services to Hospital Patients

This Attestation Statement is submitted to:

Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, VA 20153

The undersigned hereby attests, on behalf of West Virginia Department of Health and Human Resources, that West Virginia Department of Health and Human Resources had an arrangement with an independent lab in effect as of July 22, 1999, under which the independent lab billed the Medicare carrier directly for the technical component of anatomic pathology services provided by it for hospital patients. The undersigned is authorized to sign this statement on behalf of [Hospital Name].

Hospital Organization (Please Print):
Legal Name of Hospital Organization
Street Address
City, State, Zip
Medicare Provider Number:
By: [Signature of authorized hospital representative]
[Printed Name]
Attestation Date:

### WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES

# BUREAU FOR BEHAVIORAL HEALTH AND HEALTH FACILITIES Reference Laboratory Services OPEN END CONTRACT - BHS12155 Bid Sheet

0016

**EXHIBIT B (Vendor's Attachment of Phlebotomy Services)** 

•		Column A	Column B	Column C
	Facility	Estimated Annual Draws	Rates per Draw for Phlebotomy services (ali inclusive)	Total (A x B)
1	Hopemont Hospital	5	\$6.00	\$30.00
2	Lakin Hospital	520	\$6.00	\$3,120.00
3	Pinecrest Hospital	390	\$6.00	\$2,340.00
4	John Manchin Sr. HCC	5		\$30.00
5	M.M. Bateman Hospital	5	\$6.00	\$30.00
6	W. R. Sharpe Jr. Hospital	5	\$6.00	\$30.00
7	Welch Community Hospital	5	\$6.00	\$30.00
			Total of Exhibit B – Bid Sheet	\$5,610,00
			Total of Exhibit A – Bid Sheet	\$470,211.10
			Total of Exhibit B – Bid Sheet	
			Grand Total = Exhibit A + B	15475.821.10

Vendor Name: Quest Diagnostics Nichols Institute
Vendor Address: 14225 Newbrook Drive
Chantilly, VA 20151
Remit to Address: 12436 Collections Center Drive
Chicago, IL 60693
Phone #: 724-433-7430 (John Pickering, Main Contact)
Fax #: 610-271-8814 (John Pickering, Main Contact)
E-mail:John.D _p Pickering@QuestDiagnostics.com (John Pickering, Main Contact)
Signature: 05/02/12 (Dr. Nathan Sherman, Managing Director)
Date

^{**}Award will be made to lowest bidder meeting specifications.**

#### State of West Virginia

#### **VENDOR PREFERENCE CERTIFICATE**

Certification and application* is hereby made for Preference in accordance with **West Virginia Code**, §5A-3-37. (Does not apply to construction contracts). **West Virginia Code**, §5A-3-37, provides an opportunity for qualifying vendors to request (at the time of bid) preference for their residency status. Such preference is an evaluation method only and will be applied only to the cost bid in accordance with the **West Virginia Code**. This certificate for application is to be used to request such preference. The Purchasing Division will make the determination of the Resident Vendor Preference, if applicable.

	will make the determination of the Resident Vendor Preference, if applicable.
1. N/A N/A	Application is made for 2.5% resident vendor preference for the reason checked:  Bidder is an individual resident vendor and has resided continuously in West Virginia for four (4) years immediately preceding the date of this certification; or,  Bidder is a partnership, association or corporation resident vendor and has maintained its headquarters or principal place of business continuously in West Virginia for four (4) years immediately preceding the date of this certification; or 80% of the ownership interest of Bidder is held by another individual, partnership, association or corporation resident vendor who has maintained its headquarters or principal place of business continuously in West Virginia for four (4) years immediately preceding the date of this certification; or,  Bidder is a nonresident vendor which has an affiliate or subsidiary which employs a minimum of one hundred state residents and which has maintained its headquarters or principal place of business within West Virginia continuously for the four (4) years immediately preceding the date of this certification; or,
2. N/A	Application is made for 2.5% resident vendor preference for the reason checked:  Bidder is a resident vendor who certifies that, during the life of the contract, on average at least 75% of the employees working on the project being bid are residents of West Virginia who have resided in the state continuously for the two years immediately preceding submission of this bid; or,
3. N/A	Application is made for 2.5% resident vendor preference for the reason checked:  Bidder is a nonresident vendor employing a minimum of one hundred state residents or is a nonresident vendor with an affiliate or subsidiary which maintains its headquarters or principal place of business within West Virginia employing a minimum of one hundred state residents who certifies that, during the life of the contract, on average at least 75% of the employees or Bidder's affiliate's or subsidiary's employees are residents of West Virginia who have resided in the state continuously for the two years immediately preceding submission of this bid; or,
4. N/A	Application is made for 5% resident vendor preference for the reason checked:  Bidder meets either the requirement of both subdivisions (1) and (2) or subdivision (1) and (3) as stated above; or,
N/A 5. N/A	Application is made for 3.5% resident vendor preference who is a veteran for the reason checked: Bidder is an individual resident vendor who is a veteran of the United States armed forces, the reserves or the National Guard and has resided in West Virginia continuously for the four years immediately preceding the date on which the bid is submitted; or,
6. N/A	Application is made for 3.5% resident vendor preference who is a veteran for the reason checked: Bidder is a resident vendor who is a veteran of the United States armed forces, the reserves or the National Guard, if, for purposes of producing or distributing the commodities or completing the project which is the subject of the vendor's bid and continuously over the entire term of the project, on average at least seventy-five percent of the vendor's employees are residents of West Virginia who have resided in the state continuously for the two immediately preceding years.
requirer against	inderstands if the Secretary of Revenue determines that a Bidder receiving preference has failed to continue to meet the nents for such preference, the Secretary may order the Director of Purchasing to: (a) reject the bid; or (b) assess a penalty such Bidder in an amount not to exceed 5% of the bid amount and that such penalty will be paid to the contracting agency cted from any unpaid balance on the contract or purchase order.
	nission of this certificate, Bidder agrees to disclose any reasonably requested information to the Purchasing Division and es the Department of Revenue to disclose to the Director of Purchasing appropriate information verifying that Bidder has paid

Under penalty of law for false swearing (West Virginia Code, §61-5-3), Bidder hereby certifies that this certificate is true and accurate in all respects; and that if a contract is issued to Bidder and if anything contained within this certificate changes during the term of the contract, Bidder will notify the Purchasing Division in writing immediately.

the required business taxes, provided that such information does not contain the amounts of taxes paid nor any other information

Bidder: Quest Diagnostics Nichols Institute, Inc.	Signed: ////////////////////////////////////
Date: 05/02/12	Title: Managing Director

deemed by the Tax Commissioner to be confidential.

^{*}Check any combination of preference consideration(s) indicated above, which you are entitled to receive.

RFQ No. BHS12155

#### STATE OF WEST VIRGINIA Purchasing Division

#### PURCHASING AFFIDAVIT

West Virginia Code §5A-3-10a states: No contract or renewal of any contract may be awarded by the state or any of its political subdivisions to any vendor or prospective vendor when the vendor or prospective vendor or a related party to the vendor or prospective vendor is a debtor and the debt owed is an amount greater than one thousand dollars in the aggregate.

#### **DEFINITIONS:**

"Debt" means any assessment, premium, penalty, fine, tax or other amount of money owed to the state or any of its political subdivisions because of a judgment, fine, permit violation, license assessment, defaulted workers' compensation premium, penalty or other assessment presently delinquent or due and required to be paid to the state or any of its political subdivisions, including any interest or additional penalties accrued thereon.

"Debtor" means any individual, corporation, partnership, association, limited liability company or any other form or business association owing a debt to the state or any of its political subdivisions. "Political subdivision" means any county commission; municipality; county board of education; any instrumentality established by a county or municipality; any separate corporation or instrumentality established by one or more counties or municipalities, as permitted by law; or any public body charged by law with the performance of a government function or whose jurisdiction is coextensive with one or more counties or municipalities. "Related party" means a party, whether an individual, corporation, partnership, association, limited liability company or any other form or business association or other entity whatsoever, related to any vendor by blood, marriage, ownership or contract through which the party has a relationship of ownership or other interest with the vendor so that the party will actually or by effect receive or control a portion of the benefit, profit or other consideration from performance of a vendor contract with the party receiving an amount that meets or exceed five percent of the total contract amount.

**EXCEPTION:** The prohibition of this section does not apply where a vendor has contested any tax administered pursuant to chapter eleven of this code, workers' compensation premium, permit fee or environmental fee or assessment and the matter has not become final or where the vendor has entered into a payment plan or agreement and the vendor is not in default of any of the provisions of such plan or agreement.

Under penalty of law for false swearing (West Virginia Code §61-5-3), it is hereby certified that the vendor affirms and acknowledges the information in this affidavit and is in compliance with the requirements as stated.

#### WITNESS THE FOLLOWING SIGNATURE

Vendor's Name: Quest Diagnostics Nichols Institute, In	c.
Authorized Signature:	Date: 4/27/2012
State of Virginia  County of Fairfax, to-wit:	' '
Taken, subscribed, and sworn to before me this 27 day	of <u>April</u> , 2012.
My Commission expires <u>October 31</u>	, 20 <u>15</u> .
AFFIX SEAL HERE	NOTARY PUBLIC Chlocolane Vitalis





# **Position Paper**

The Provision of Laboratory Services Does Not Make Quest Diagnostics a Business Associate of Other Covered Entities

Quest Diagnostics does not become a business associate (as that term is defined in the HIPAA Privacy Rule) of another covered health care provider, such as a hospital or physician, by providing laboratory services to that covered health care provider.

The final Privacy Rule, at § 164.506, makes it clear that any covered entity, including Quest Diagnostics, as well as referring physicians or hospitals, is permitted to make disclosures of protected health information to another health care provider for treatment purposes, to health plans for payment purposes, and to other covered entities for either party's health care operations purposes. This section reads as follows:

- § 164.506 (c) <u>Implementation specifications: Treatment, payment, or health care</u> operations.
- (1) A covered entity may use or disclose protected health information for its own treatment, payment, or health care operations.
- (2) A covered entity may disclose protected health information for treatment activities of a health care provider.
- (3) A covered entity may disclose protected health information to another covered entity or a health care provider for the payment activities of the entity that receives the information.
- (4) A covered entity may disclose protected health information to another covered entity for health care operations activities of the entity that receives the information, if each entity either has or had a relationship with the individual who is the subject of the protected health information being requested, the protected health information pertains to such relationship, and the disclosure is:
- (i) For a purpose listed in paragraph (1) or (2) of the definition of health care operations; or
- (ii) For the purpose of health care fraud and abuse detection or compliance.

A business associate relationship is required only when an entity is acting "on behalf of" a covered entity or is providing specified services (such as legal or accounting services) to a covered entity. The Department of Health and Human Services has made it clear that not every exchange of protected health information between a covered entity and another entity results in the establishment of a business associate relationship:

Quest Diagnostics has a HIPAA compliance program to ensure its adherence to the requirements of the HIPAA Privacy & Security Rules. This Position Paper is not intended to serve as legal advice and should not be relied upon as such. Other covered entities should review the facts and the law with their own legal counsel and obtain separate legal advice.

# Interface Build Project Plan Quest Diagnostics Nichols Institute Chantilly

Task Description	Resp.	Est Time	Wk1	Wk 2	Wk3	Wk 4	Wk 5	Wk 6	Wk7	Wk 8	Wk 9	WE 10	Wk 11	W/2 42	1ATE 42	Wk 14	I WE 45	Wk 16	10/1/ 47	1
Project Request/Definition - 3 weeks	1000	Lac mile	***	****	TTN 3	JVA 4	*****	VVK	WAY .	VVAG	E AVV	VVR 10	WALL	FVK 1Z	VVK 13	47K 14	97K 15	VVK 16	AAK 11	-
Client provided with "Get Connected" questionnaire	Q	1 day	ing594660(164		<del> </del>	-	·····		<del> </del>	<del> </del>		<del>                                     </del>	<del> </del>	·····	-	<del> </del>	<del>                                     </del>		-	
Client completes "Get Connected" questionnaire	č	2 weeks	120000000000000000000000000000000000000	datatapataban								-	<del></del>							<del> </del>
Client requests/receives Reference Lab Interface quote from vendor	- 3	2 weeks	dokajuoas	1026361036	<del>                                     </del>				<u> </u>	<del> </del>		<del></del>	<del></del>			<del> </del>	<del> </del>		<del> </del>	_
Sales Rep requests Chantilly LIS Account number(s)	a	1 day	MORROWANIA MORROWANIA	- construings house								<del></del>		ļ		<del> </del>				<del> </del>
Sales Rep requests Care360 system for Client	<del>- 2</del>		20/00/00/00/00/	ļ							-		<del></del>		<del></del>	<del> </del>	ļ		-	ļ
		1 day	ansy isaning		<del> </del>	-			<b></b>						<del></del>	ļ				ļ
Sales Rep requests Consultant to assist in Interface Database Build	a	1 day	matical folia						ļ	<del> </del>		ļ			ļ					<del>                                     </del>
Sales Rep schedules "Get Connected" call (Project Kickoff)	Q	1 day		1045500000000		ļ		ļ	ļ	-					<u> </u>	ļ				<b></b>
Sales Rep provides test code utilization to IT	0	1 day	·	,0000000000000000000000000000000000000							<b>└</b>	ļ			ļ					ļ
"Get Connected" Call (Project Kickoff)											1								İ	l
Define project roles and responsibilities										[									İ	l
Establish weekly conference calls																				
Define interface testing process	Q/C/V	1 day			\$16509X	1				1										l
Define interface parameters		''									l								İ	l
Define bar code label and specimen manifest									1		i									l
Agree on test list to be interfaced	l			l							1					1	1	l	1	l
Establish interface timeline and target go-live date					73.00	L !		L	L		Щ	L				L	L	L	<u></u>	L
Implementation Analyst Assigned to Project	Q	1 day			MAKE MINISTRA											I			Ĭ	
Client provided with VPN connectivity questionnaire	Q	1 day			ishii yuniyi					1							T		***************************************	····
Client completes VPN connectivity questionnaire	С	1 week			15550 5551500						····					<u> </u>		T	T	
	l									T	· · · · · · · · · · · · · · · · · · ·	i					l			<del> </del>
Interface Configuration - 2 weeks	T	i			i	i			<b></b>		l				<del> </del>	-				<del> </del>
Load Interface programs & hardware	ĊΝ	1 week			<b></b>	377876353703			<del> </del>						<u> </u>	<del>                                     </del>	<u> </u>	<del></del>	<del></del>	
Set up Client interface at Chantilly (in Test System)	à	1 wook			l	339013080210935			<del> </del>	<b>———</b>	· · · · · · · · · · · · · · · · · · ·			******	<del> </del>					<del></del>
Client Care360 system implementation (web based)	Q/C	1 day				OHOTO PAGE			<del> </del>	<del> </del>		<b></b>			<u> </u>	1	<del></del>	<del></del>	<del> </del>	<del> </del>
Client provides Interface Database Consultant with remote connectivity	- C	1 week				N. (1000) 200				<del> </del>		<del> </del>				<del>                                     </del>				
Provide maps for building tests	ᅥᇹ	2 weeks		-		STREET, STANS	010000000000		<u> </u>		ļ					<del>                                     </del>	-			
Establish communications	0/0//	2 weeks		<del></del>	<del></del>	Sacrimental von	monte (cesto)		<del> </del>	<del>                                     </del>	<del> </del>	<b></b>			<del></del>	<del> </del>			<del> </del>	
LONDROTT COSTUSTACIONALIS		~ Accus			<del></del>	(a.55+(155))(d)	151511404164501					<b></b>				-		<del> </del>	<u> </u>	
Interface Validation - 3 weeks	<del> </del>											<b></b>			<del>                                     </del>			-		-
Build 20 tests for functionality testing	Q/C	1 week		-	<del></del>	<del> </del>		632500000375700	<del> </del>		<del>                                     </del>		-		ļ	<del> </del>	<del> </del>			
Functionality Testing:	1 2/0	, 19801			<del></del>			#130 (#1320)A23	\$123562/5655104 ³	\$45556454955	<del> </del>	<b></b>			<del> </del>	<del> </del>		<b></b>	-	-
- Test complete loop orders in & results out	l				1				Perented		l				l			1		1
Verify label — bar code & Chantilly acct #									NG ASSI		l				l			l		
Verify manifest – Client name & Chantilly acct #																				
Test basic order/result functionality	Q/C/V	3 weeks																		
	Q/C/V	3 Weeks									ł									
Test exceptions (add, cancel, corrected)								9000048		Man Mark	l									
Test parameter settings (partial reports, multiple Pts, flagging, etc.)											1									
- Test reflex tests											l				l					
Verify report formats	<u> </u>					ļ		MANUAL WAR	neronjarititi	SMNUANA.										<u> </u>
	<u> </u>								<b></b>		ļ	<u> </u>	<u> </u>							
Interface Database Build and Test - 4 weeks	<u> </u>										L						L	L		
Build/test/verify 10-20 tests/day (minimum 200 tests)	Q/C	4 weeks									RESIDENCE	20000000000000000000000000000000000000	SHERISH	349931832541						
Verify Report formats	Q/C	4 weeks									STANSPORT	AMERICAN	9(8)349(44)	990(25)						
Implementation -1 week																				
Confirm "Go-Live" Date	Q/C/V	1 day													MARINARA					
Review operational issues	Q/C	1 day													\$100 GENERAL					
Train users	С	1 week								T					angemenn)		l			
Decide on final setup parameters (pending lists etc.)	Q/C	1 day							I						ANYS (1821)			T		
Move tests, setups & programs to "live" system	Q/Q/V	1 week							· · · · · · · · · · · · · · · · · · ·						300000000		l			i
Activate the interface for first 200 tests (Go Live)	Q/C/V	1 day	SALVARDISMA		15.000000000000000000000000000000000000	(6000EE)000	CHICAGON A		KARANTA MARKA	20X2001X2400	300/75/75	ANSON COURT	STATE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE	KARATA KARATA	LIVE		<del> </del>	i		i
, and the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of									<b>*******</b>	l						1				<del> </del>
Post Implementation - 4 weeks	1							***************************************										<b></b>		<del>                                     </del>
Monitor transactions	Q/C/V	4 weeks			<del> </del>			-			<b> </b>	-		_	<del> </del>	SEER CHANGE	SHEESEN WAS STROME	266270335533554	2012/04/05/25/01/05/0	<del> </del>
Wrap-up conference/project review	Q/C/V	1 day			<del>                                     </del>	<u> </u>			<del> </del>		<del></del>				-	SALES AND THE SALES	2000 000 000 000 000 000 000 000 000 00	100000000000000000000000000000000000000	115 (0.119 (mm/s) (16)	$\vdash$
Transfer interface to maintenance support	Q/C/V	1 day			<del> </del>					_		<del> </del>			<del> </del>				2005 200 E	<del> </del>
тальна вненасе то траптелансе вирроп	U/U/V	Gay			-					<del> </del>	ļ <u>.</u>	-				September 1		:34(8)(25(8))	2005 005 002	
0	<del> </del>				-						<b> </b>				<del> </del>	ļ		ļ		
Ongoing		A														ated a became at the Com-	None control to the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the control of the c			
Continue to build/test/verify until all tests are built in interface	Q/C	Ongoing							ļ		ļ					Philo C.	est until d	atabase c	omplete	
	i											·			ļ				L	
	:				L	!					1	1								!



# Accredited Laboratory



# The College of American Pathologists

certifies that the laboratory named below

Quest Diagnostics Nichols Institute dba Quest Diagnostics Nichols Institute Chantilly, Virginia Kenneth L. Sisco, MD,PhD

LAP Number: 1361101

AU-ID: 1179154

CLIA Number: 49D0221801

has met all applicable standards for accreditation and is hereby fully accredited by the College of American Pathologists' Laboratory Accreditation Program. Reinspection should occur prior to April 22, 2013 to maintain accreditation.

Accreditation does not automatically survive a change in director, ownership, or location and assumes that all interim requirements are met.

Frank & Rusy

Chair, Commission on Laboratory Accreditation

Stock & Bau MO FCAP

President, College of American Pathologists

# CENTERS FOR MEDICARE & MEDICAID SERVICES CLINICAL LABORATORY IMPROVEMENT AMENDMENTS CERTIFICATE OF ACCREDITATION

LABORATORY NAME AND ADDRESS QUEST DIAGNOSTICS NICHOLS INSTITUTE QUALITY ASSURANCE 14225 NEWBROOK DRIVE CHANTILLY, VA 20151 CLIA ID NUMBER 49D0221801

EFFECTIVE DATE 02/09/2011

LABORATORY DIRECTOR
KENNETH L SISCO, MD, PHD

EXPIRATION DATE 02/08/2013

Pursuant to Section 353 of the Public Health Services Act (42 U.S.C. 263a) as revised by the Clinical Laboratory Improvement Amendments (CLIA), the above named laboratory located at the address shown hereon (and other approved locations) may accept human specimens for the purposes of performing laboratory examinations or procedures.

This certificate shall be valid until the expiration date above, but is subject to revocation, suspension, limitation, or other sanctions for violation of the Act or the regulations promulgated thereunder.

Gutth G. Yan

Judith A. Yost, Director Division of Laboratory Services Survey and Certification Group Center for Medicaid and State Operations

CIVIS/

If you currently hold a Certificate of Compliance or Certificate of Accreditation, below is a list of the laboratory specialties/subspecialties you are certified to perform and their effective date:



## Policy for Priority Result Reporting

#### Purpose/Introduction

The Quest Diagnostics Priority Result Reporting Policy describes the reporting of test results, as designated by the Chief Laboratory Officer and Best Practice Team Medical Advisors, which may require attention by the healthcare provider prior to regular delivery of results. The priority result reporting described in this policy is in addition to the regular reporting procedure for all test results (such as printed reports delivered by mail).

The provider who requested the test is responsible for providing 24-hour reliable contact information for the purpose of priority reporting. The person notified should be the ordering provider or her/his authorized representative as permitted or required by state and federal law, and has the responsibility of interpreting the result in the context of the patient's clinical condition and to take immediate action, if needed. If the person notified is not qualified to make these decisions, he/she has the responsibility to communicate the information to a qualified person immediately.

#### **Priority Level Definitions**

**Priority-1** test results include, but are not limited to, results considered "critical" according to the Clinical Laboratory Amendments of 1988 (CLIA; CFR 493.1109f) and the College of American Pathologists (CAP) Laboratory Accreditation Program and so designated by the Chief Laboratory Officer or designee.

Because test results cannot be fully interpreted without knowledge of the patient's current clinical condition and treatment, we will use reasonable efforts to promptly communicate Priority-1 results at any hour of the day, 7 days/week so that the healthcare provider can determine the clinical implications and possible need for immediate attention.

**Priority-2** test results are those that may require attention prior to the receipt of routine laboratory reports. We will use reasonable efforts to promptly communicate these results the same day (up to 7pm) or the next morning (after 7am), 7 days/week. Tests marked Priority 2WD are called between 7 am and 7 pm weekdays. For facilities that are known to us as a nursing home or hospital, we will use reasonable efforts to promptly communicate these results at any hour of the day, 7 days/week.

Priority-3 reporting applies only to customers whose sole means of obtaining Quest Diagnostics laboratory results is the printed report (i.e., receiving only mailed or courier-delivered reports) and to clients who have requested Priority-3 reporting in writing during the previous 12 months. These are test results that may require attention before receipt of the printed report and will be called during weekday working hours.

The attached Priority Value Table will not be modified (changed, deleted from, or added to) without the signed written request of the client.

Chemistry / Special Chemistry	Priority (For eller	3 (called 7am its without elec	ı – 7pm M − F) ctronic reporting)	Priority :	2 (called 7am	– 7pm 7 days)	Priority 1 (called 24 hrs 7 days)				
Analyte	Age	Low	High	Age	Low	High	Age	Low	High		
Ammonia [umol/L]							≤18 y		> 200		
Amylase [U/L]				All		≥ 300					
Glomerular Basement Membrane Antibody IgG [U/mL]							All		> 8		
Bilirubin, total [mg/dL]	≤2y		12.1 14.9				≤2 y		≥ 15.0		
Bilirubin, total [mg/dL]	> 2 y		> 20.0								
BUN[mg/dL]				All		≥ 100	(International Property of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Control of the Contr				
Calcium, Total [mg/dL]							All	≤ 6.0	≥ 13.0		
Calcium, Ionized [mg/dL]							All	≤ 3.2	> 6.9		
СК <b>–</b> МВ	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s			All		> positive cutoff value (varies with assay)	The Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control of Control				
CK (U/L)				≤ 18 y		≥ 1000					
CK [U/L]				> 18 y		≥ 6000			-		
Complement levels	< 2 y	None detected									
Creatinine [mg/dL]				All		≥ 8.00					
Galactose, urine [mg/dL]				≤2y		> 70					
Galactose – 1 – Phosphate [mg/dL packed RBC]				≤2 y		> 5.0					
Glucose, serum [mg/dL]  "Glucose results are flagged P1 – P3 regardless of ordered test (OGTT, random glucose, serum or plasma, etc.). When these results are called to the client, the report title of the test result should be made known to the client.	Ali		400 – 499	All	30 – 35	500-599	All	< 30	≥ 600		
Glucose, CSF, [mg/dL]							All	<30			
ron (serum) [mcg/dL]	≤12 y		≥ 500								
.ipase [U/L]				All		≥ 180					
flagnesium serum or plasma [mg/dL]							All	≤ 0.7	≥ 6.1		
Phosphate (as phosphorous) serum or plasma [mg/dL]							All	≤ 1.0			

Chemistry / Special Chemistry	Priority 3 ( (For clients	called 7am without elect	−7pm M − F) ronic reporting)	Priority 2	(called 7ar	n – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Potassium serum or plasma [mmol/L]	<u> </u>			ĺ			All	≤ 2.7	≥ 6.5	
Sodium serum or plasma [mmol/L]							All	≤ 120	≥ 160	
Troponin (I or T)							All		Positive > cutoff value	
TSH [mIU/L]			***************************************	≤1y		≥ 50.00				
Uric Acid, [mg/dL]				All		>12.0		<u> </u>		
Viscosity (serum) [relative to water]							Ail		≥ 3.0	

Hematology <i>I</i> Coagulation <i>I</i> Urinalysis	Priority (For clier	3 (called 7am its without elec	− 7pm M − F) tronic reporting)	Priority	2 (called 7am	– 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Blasts, absolute number [/uL]				All		Blasts >0 (new patient only)	All		≥ 50,000 on any patient	
Cerebrospinal fluid (CSF)							All		Any abnormal per local Med. Director	
Coagulation Factors VIII & IX, Activity [%]				All	< 5					
Coagulation Factor XIII, Activity [%]				All	< 20	***************************************				
Coagulation Factor VIII, IX and XI Inhibitor [Bethesda Unit]				All		> 2				
Cryoglobulin [%]		***************************************		All		> 3				
Fibrinogen Clotting Activity, Clauss Method [mg/dL]				All	< 50					
Heparin, unfractionated [IU/mL]				All		> 1.10				
Heparin, low molecular weight [IU/mL]	İ	17.07		Ali		> 2.0				
Heparin - Induced Platelet Antibody				All		Positive				
Serotonin Release Assay [%]				All		≥ 20				
Von Willebrand Factor Protease Cleaving Activity [%]				All	≤ 30					
Glucose (Urinalysis)	≤ 16 y		3+ or higher							
Hemoglobin [g/dL]				≥ 12 y	7.0 - 8.9		≤ 12 y	< 7.0	≥ 22.5	
Hemoglobin [g/dL]				> 12 y	6.1 7.0		> 12 y	≤ 6.0	≥ 22.5	
Malaria parasites or other organisms (Babesia, Ehrlichia, Trypanosomes etc.) [also appears in Microbiology section]				All		Positive for blood parasites or <i>Plasmo-dium</i> species other than <i>P falciparum</i>	All		Positive for verified P falciparum or unidentified "Plasmodium species"	
WBC, absolute number [/uL]				All	< 1,000					
Neutrophils, absolute number [/uL]				All		> 30,000	All	< 400		
Band neutrophils [/uL]	All		> 10,000	:						
Partial Thromboplastin Time,(aPTT) [sec.]	All		60 – 89		1		All		≥ 90	
Platelet Count [/uL]	All	20,000 50,000	1,000,000 — 1,999,999				All	< 20,000	≥ 2,000,000	
Prothrombin Time-International Normalized Ratio (PT-INR)	All		4.0 - 4.9	All		5.0 – 7.9	All		≥ 8.0	
Reducing Substance (Urinalysis, Clinitest)	≤2 y		Positive							

Microbiology / Serology	Priority 3 (For clients	(called 7an without ele	n – 7pm M – F) ctronic reporting)	Priority 2	2 (called 7a	ım – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Bacillus anthracis, culture, nucleic acid, or antigen test							All		Positive	
Bacterial meningitis antigens, CSF							All		Positive	
Bordetella pertussis, culture, nucleic acid, or antigen				All		Positive				
Bordetella parapertussis, culture, nucleic acid, or antigen				All		Positive				
Brucella sp., culture, nucleic acid or antigen test							All		Positive	
Chlamydia trachomatis, culture, nucleic acid or antigen test				< 13 y		Positive			*	
Clostridium difficile toxin A, B, A+B or toxigenic culture, stool (Note: non-toxigenic strains should not be called)				All		Positive				
Corynebacterium diphtheriae, nasopharynx culture				All		Positive				
Cryptococcus antigen, serum or CSF							All		Detected	
Culture: blood, CSF, any tissue or sterile body fluid (excluding urine)				All		FINAL: positive any organism	All		PRELIM: positive any organism	
Enterobacteriaceae isolates, Carbapenemase producing (Hodge test positive)				All		Positive for Carbapenemase				
E coli O157, culture, stool				All		Positive			***************************************	
Francisella tularensis, culture, nucleic acid, or antigen test							All		Positive	
Gram or other stain of direct specimen or antigen detection (blood, CSF, sterile body fluid)							AII		Positive for any micro- organism	
Nucleic acid detection (blood, CSF, sterile body fluid), qualitative FIRST DETECTION ONLY				All		Positive for HBV, HCV, HIV	All		Positive for any micro-organism except HBV, HCV, HIV	
Gram or other stain of direct specimen or antigen or nucleic acid detection (tissue)				All except for skin or wound		Positive or detected			***************************************	
Histoplasma, Blastomyces, Coccidiodes, Paracoccidiodes, or Cryptoccocus neoformans isolated and/or detected by microscopy, nucleic acid or antigen tests				All		Positive				

Microbiology / Serology	Priority 3 (called 7am – 7pm M – F) (For clients without electronic reporting)			Priority	2 (called 7a	am – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Influenza A and/or B (includes positive H1N1 test results), culture, nucleic acid, or antigen test	All		Positive							
Legionella sp., culture, nucleic acid, or antigen test				All		Positive				
Malaría parasites or other organisms (Babesia, Ehrlichia, Trypanosomes etc.)  [also appears in Hematology section]		and the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second s		All		Positive for blood parasites or Plasmodium species other than P. falciparum	All		Positive for verified P. falciparum or unidentified "Plasmodium"	
	l					r, laluparulli			species"	
MRSA culture: Patients in institutional settings ONLY	All		Positive							
MRSA, PCR or other nucleic acid test				All		Detected				
Mucormycosis/Zygomycosis involving sino nasal area				All		Positive				
Mycobacteria all sp., stain or direct specimen nucleic acid test for M tuberculosis, initial detection							All		Positive	
Mycobacteria all sp., culture, initial detection and final identification.				All		. Positive	•			
Mycobacteria tuberculosis, susceptibilities, resistant to 2 or more drugs				All		Resistant ≥ 2				
Neisseria gonorheoeae, culture or nucleic acid test				< 13y		Positive				
Nocardia species				All		Positive				
Pneumocystis jiroveci (carinii), stain or antigen test				All		Positive				
Respiratory syncytial virus (RSV), culture, nucleic acid or antigen test	> 3 y		Positive	≤3 y		Positive				
Rotavirus, antigen test				All		Positive				
Shiga Toxin, EIA				Ali		Detected				
Stool Culture, Shigella sp., Listeria sp., Salmonella sp., Campylobacter sp., Vibrio sp., and/or Yersinia enterocolitica				All	The state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the s	Positive				
Streptococcus, Group A, wound culture				All		Positive				
Streptococcus, Group B, culture or nucleic acid test				< 1 y		Positive				
Ureaplasma urealyticum, culture, respiratory				< 1 y		Positive				

Microbiology / Serology	Priority 3 ( (For clients	Priority 3 (called 7am – 7pm M – F) (For clients without electronic reporting)				am – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Vancomycin Intermediate or Resistant Staphylococcus aureus (VISA or VRSA)	ĺ			All		Vancomycin I or R				
VRE culture	All		Positive							
VRE PCR or nucleic acid test				All		Detected			***************************************	
Yersinia pestis, culture, nucleic acid, or antigen test							All		Positive	

TDM / Toxicology	Priority 3 (called 7am – 7pm M – F) (For clients without electronic reporting)			Priority 2	2 (called 7	am – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Acetaminophen [mg/L]	İ						All		≥ 50	
Acetone [mg/dL]							All		≥ 50	
Amikacin, random [mg/L]	Aii		> 30.0				<u> </u>			
Amikacin, peak [mg/L]	Ali		> 30.0				<u> </u>			
Amikacin, trough [mg/L]	All		> 8.0		***************************************					
Amitriptyline + Nortriptyline total [mcg/L]	All		300 599	All		600 – 999	All		≥ 1000	
Amobarbital [mg/L]	All		12.1 – 19.9				All		≥ 20.0	
Arsenic, Blood [mcg/L]				All		> 60				
Butalbital [mg/L]							All		> 10.0	
Cadmium, Blood [mcg/L]				All		10.0 - 29.9	All		≥ 30.0	
Cadmium, 24hr Urine [mcg/L]							All		> 10.0	
Caffeine [mg/L]	≥1 y		30.1 - 49.9	< 1 y		40.0 – 49.9	All		≥ 50.0	
Carbamazepine, total [mg/L]	All		12.1 - 19.9				All		≥ 20.0	
Carboxyhemoglobin [% of total Hgb]	All		15 – 19			-	All		≥ 20	
Chloramphenicol, random [mg/L]	All		> 25.0							
Chloramphenicol, peak [mg/L]	All		> 25.0		* <del>}</del>		-			
Chloramphenicol, trough [mg/L]	All		> 20.0							
Chlordiazepoxide and Metabolite and (Desmethylchlordiazepoxide), total [mg/L]	All		> 5.0							
Chlorpromazine [ng/mL]	≥ 18 y		300 – 749				All		≥ 750	
Chlorpromazine [ng/mL]	< 18 y		80 – 749				All		≥ 750	
Clomipramine and Metabolite, total [ng/mL]							All		≥ 600	
Clorazepate as Nordiazepam [mg/L]	All		> 2.0				***************************************			
Cobalt, Blood [mcg/L]							All		≥ 400	
Cobalt, Urine [mcg/L]				All		≥ 250				
Cyanide [mg/L]				All		0.5 - 0.9	ΙΙΑ		≥ 1.0	
Cyclosporine, as Trough [mcg/L]	1			All		400 599	All	1	≥ 600	
Desethylamiodarone [mcg/mL]						······································	All		> 2.5	
Desipramine [mcg/L]	Ali		301 – 599			·····	All		≥ 600	
Diazepam and Nordiazepam, total [mg/L]	All		2.1 – 2.9	1			All		≥ 3.0	
Digitoxin [mcg/L]	All		36 – 44				All	<del>-  </del>	≥ 45	
Digoxin [mcg/L]	All		2.1 – 2.9				All		≥ 3.0	
Disopyramide [mg/L]	All		5.1 – 6.9				All		≥ 7.0	

TDM / Toxicology	Priority 3 (called 7am – 7pm M – F) (For clients without electronic reporting)			Priority	2 (called 7a	ım – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Doxepin + Nordoxepin, total [mcg/L]	Ali		300 – 599	İ			Ali		≥ 600	
Ethanol [mg/dL]		*****				,	All		≥ 250	
Ethosuximide [mg/L]	All		101 149				All		≥ 150	
Ethylene glycol [mg/L]				1	***************************************		All		≥ 100	
Flecainide [mg/L]							All		≥ 1.0	
Fluoxetine [mcg/L]	All		> 469							
Fluphenazine [mcg/L]	All		18 49				All		≥ 50	
Norfluoxetine [mcg/L]	All		> 446				1			
Gentamicin, random [mg/L]	All		> 10.0				T			
Gentamicin, peak [mg/L]	All		> 10.0				1			
Gentamicin, trough [mg/L]	All		> 2.0							
Haloperidol, Serum [ng/mL]				ΑII		> 20				
lbuprofen [mg/L]	All		75 99				All		≥ 100	
mipramine or Desipramine, total [mcg/L]	All		301 599				All		≥ 600	
Isopropanol [mg/dL]			,				All		≥ 50	
Lead, blood [mcg/dL]	≥6 y		> 40	<6y		20 – 44	<6y		≥ 45	
Lead, 24hr Urine [mcg/L]				All		≥ 120				
Levetiracetam, peak [mg/L]				All		> 70				
Levetiracetam, trough [mg/L]				All		> 37				
Lidocaine [mg/L]	All		5.1 – 5.9				All		≥ 6.0	
Lithium [mEq/L]	All		1.6 – 1.9				All		≥ 2.0	
Mephobarbital [mg/L]	All		40.1 - 59.9				Ali		≥ 60.0	
Mercury, Blood [mcg/L]	All		> 13				1			
Mercury, Urine, 24 hr [mcg/L]	All		36 – 149				All		≥ 150	
Mercury, Urine, Random [mcg/g creatinine]	Ali		36 – 149				All		≥ 150	
Mesoridazine [mg/L]	All		> 1.4							
Methanol [mg/dL]							All		≥5	
Methemoglobin [% of total Hgb]	All		12.0 - 69.9				All		≥ 70.0	
Methotrexate at 24 h [µmol/L]							All		≥ 5.00	
Methsuximide, as Normethsuximide [mg/L]							All		> 40.0	
Mexiletine [mg/L]				All		2.0 - 4.9	All		≥ 5.0	
Mycophenolic Acid [mcg/mL]				All	0.5 - 1.0	> 3.5	All	< 0.5		
Mycophenolic Acid Glucoronide [mcg/mL]	1		···	All	< 35.0					

TDM / Toxicology	Priority (For clie	Priority 3 (called 7am – 7pm M – F) (For clients without electronic reporting)			2 (called 7a	m – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age	Low	High	Age	Low	High	
Nortriptyline [mcg/L]	All		250 – 499				All		≥ 500	
Phenobarbital [mg/L]	All		40.1 – 59.9				All		≥ 60.0	
Phenytoin [mg/L]	All		35.1 – 39.9				All		≥ 40.0	
Phenytoin, free [mg/L]							All		> 3.0	
Primidone [mg/L]	All		12.1 – 15.0				All		> 15.0	
Procainamide [mg/L]	All		12.0 13.9				All		≥ 14.0	
Procainamide + NAPA total [mg/L]							All		> 30.0	
Protriptyline [mcg/L]	All		261 – 499				All		> 500	
Propafenone [mg/L]							All		> 2.0	
Quinidine [mg/L]	All		5.1 - 9.9				All		≥ 10.0	
Salicylates [mg/L]							All		≥ 400	
Sirolimus (Rapamycin) [mcg/L] Immunoassay				All		≥ 35.0	All	<3.0		
Tacrolimus (FK 506) [mcg/L]				All	3.0 – 4.9	> 20.0	All	< 3.0		
Theophylline [mg/L]							<6m		> 10.0	
Theophylline [mg/L]	≥6 m		20.1 – 39.9				≥6m		≥ 40.0	
Thioridazine [mg/L]	All		> 2.6							
Tobramycin, random [mg/L]	All		> 10.0							
Tobramycin, peak [mg/L]	All		> 10.0							
Tobramycin, trough [mg/L]	All		> 2.0							
Thallium, Blood [mcg/L]	All		6 – 79				All		≥ 80	
Thallium, Urine, 24 hr [mcg/L]	All		6 – 199				Ali		≥ 200	
Trazodone [mcg/L]	All		> 2,100							
Valproic Acid [mg/L]	Ali		100.1 149.9				All		≥ 150.0	
Vancomycin, random [mg/L]	All		40.1 – 79.9				Ali		≥ 80.0	
Vancomycin, peak [mg/L]	All		40.1 79.9				All		≥ 80.0	
Vancomycin, trough [mg/L]	All		> 20.0				All		≥ 80.0	
Zonisamide [mg/L]	All		> 40		ľ		1	***		

Genetic Testing	Priority 3 (For clients	(called 7am without elec	− 7pm M − F) tronic reporting)	Priority 2WD (called 7am – 7pm weekdays ONLY)	Priority	1 (called 24	hrs 7 days)
Analyte	Age	Low	High	Age Low High	Age	Low	High
Ashkenazi Jewish Panel (8 test or 11 test)					Í		
Bloom Syndrome DNA Mutation Analysis							
Canavan Disease Mutation Analysis							
Cystic Fibrosis Screen				·			
Familial Dysautonomia Mutation Analysis				Heterozygous for mutation			
Fanconi's Anemia DNA Mutation Analysis				or not interpretable			
Gaucher Disease, DNA Mutation Analysis							
Glycogen Storage Disease Type Ia Mutation Analysis				Note: Homozygous disease states are directly called by the performing			
Maple Syrup Disease (MSUD) Mutation Analysis (Ashkenazi Jewish)				laboratory			
Mucolipidosis Type IV Mutation Analysis							
Niemann-Pick Disease Mutation Analysis							
Tay-Sachs Disease Mutation Analysis					7-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		,
Amniotic fluid open neural tube defect screen				MOM value ≥ 2.0 MOM			
XSense [®] , Fragile X with Reflex				Gray zone, pre-mutation or affected result			
Maternal Serum Biochemical Screening				MSS Interpretation- Screen positive for ONTD, Down syndrome and/or trisomy 18 or High risk for Down syndrome and/or trisomy 18			

Pathology / Hematopathology			– 7pm M – F) tronic reporting)	Priority 2 (called 7am – 7pm 7 days)	Priority 1 (called 24 hrs 7 days)			
Analyte	Age	Low	High	Age Low High	Age Low High			
Gyn Cytology (Pap)				HSV, if pregnancy indicated in LIS     Adenocarcinoma in situ     Suspicious for malignancy     Positive for malignancy**				
Non – Gyn Cytology				Suspicious for malignancy     Positive for malignancy**				
Hematopathology (including Flow Cytometry, FISH, and Molecular)				Positive for acute leukemia (initial or recurrence)	First time diagnosis of acute promyelocytic leukemia			
Tissue Biopsy				POC without identifiable placental villi or fetal parts Suspicious for malignancy** Positive for malignancy** Significant unexpected surgical pathology findings as determined by pathologist	Frozen section results     Presence of adipose tissue in an endometrial biopsy			
				diagnosed malignancy but includes case report. It is not intended that pre-maligna complex endometrial hyperplasia, etc. be unless the pathologist has made an addi	ase findings to the list (e.g., bcc/scc with			



#### CERTIFICATE OF LIABILITY INSURANCE

DATE (MM/DD/YYYY) 12/30/2011

THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER.

IPORTANT: If the certificate holder is an ADDITIONAL INSURED, the policy(ies) must be endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the certificate holder in lieu of such endorsement(s).

			, ,			_				
1 1	DUCER IARSH & MCLENNAN COMPANIES 186 AVENUE OF THE AMERICAS IEW YORK, NY 10036				CONTAC NAME: PHONE (A/C, No E-MAIL	, Ext):		FAX (A/C, No):		
	Illn: sharon.e.smith@marsh.com (212) 345-3522				ADDRES				·····	1
370	36 -MAIN-ALL-11-12					INS Travelers f	rop. Casualty Co	DING COVERAGE Of America		NAIC# 25674
INSU	THE STANSAULT			d PALA	INSURE	25658				
	UEST DIAGNOSTICS INCORPORATED GIRALDA FARMS						nsurance Compa			19437
	IADISON, NJ 07940				INSURE			··· <b>·</b>		
					INSURE	TO STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE STATE OF THE ST				
					INSURE					
CO	VERAGES CER	TIFIC	CATE	NUMBER:		006306014-23		REVISION NUMBER:		
IN C	HIS IS TO CERTIFY THAT THE POLICIES IDICATED. NOTWITHSTANDING ANY REERTIFICATE MAY BE ISSUED OR MAY KCLUSIONS AND CONDITIONS OF SUCH	EQUIF PERT	reme 'ain.	NT, TERM OR CONDITION THE INSURANCE AFFORD	OF ANY	CONTRACT	OR OTHER I	DOCUMENT WITH RESPECT TO	OT TO	WHICH THIS
INSR LTR	TYPE OF INSURANCE		SUBR WVD			POLICY EFF (MM/DD/YYYY)	POLICY EXP	LIMIT	8	
	GENERAL LIABILITY  COMMERCIAL GENERAL LIABILITY  CLAIMS-MADE OCCUR							EACH OCCURRENCE DAMAGE TO RENTED PREMISES (Ea occurrence) MED EXP (Any one person)	\$ \$ \$	
								PERSONAL & ADV INJURY	\$	
								GENERAL AGGREGATE	\$	
	GEN'L AGGREGATE LIMIT APPLIES PER:							PRODUCTS - COMP/OP AGG	\$	
	POLICY PRO- JECT LOC			YOU IOAD OCCTOCOO TIL 44		4010410044	40/04/0040	COMBINED SINGLE LIMIT	\$	
	AUYOMOBILE LIABILITY			TC2JCAP-266T3603-TIL-11	12/31/20	12/31/2011	12/31/2012	(Ea accident)	\$	3,000,000
	ALL OWNED SCHEDULED							BODILY INJURY (Per person)	\$	
	AUTOS AUTOS NON-OWNED							PROPERTY DAMAGE	\$	
	HIRED AUTOS AUTOS		İ					(Per accident)	\$	
С	UMBRELLA LIAB OCCUR			8125869		12/31/2011	12/31/2012	EACH OCCUPRENCE	\$	5,000,000
	X EXCESS LIAB X CLAIMS-MADE							AGGREGATE	\$	5,000,000
	DED X RETENTION \$ 2,000,000			GL-Self Insured Retention				AGGREGATE	\$	
Α	WORKERS COMPENSATION		·	TC2JUB-266T3523-11 (DED)		12/31/2011	12/31/2012	X WC STATU- OTH- TORY LIMITS ER	<u> </u>	
В	AND EMPLOYERS' LIABILITY  ANY PROPRIETOR/PARTNER/EXECUTIVE  N  OFFICER/MEMBER EXCLUDED?			TRKUB-266T3535-11 (RETRO)		12/31/2011	12/31/2012	E.L. EACH ACCIDENT	\$	2,000,000
	(Mandatory in NH)	N/A						E.L. DISEASE - EA EMPLOYEE	\$	2,000,000
	If yes, describe under DESCRIPTION OF OPERATIONS below							E.L. DISEASE - POLICY LIMIT	\$	2,000,000
	CRIPTION OF OPERATIONS / LOCATIONS / VEHICI									
(Profe	ssional Liability / Claims Made - Self Insured Reter	ntion -	\$5,0	00,000 - 12/31/11 - 12/31/12) *E	VIDENCE	OF COVERAGE	ONLY*			
GENE	RAL AND PROFESSIONAL LIABILITY INSURANCE	IS INC	LUDFI	D UNDER THE EXCESS HARILITY	COVERA	GF.				
CF	RTIFICATE HOLDER				CANC	ELLATION				
<u>VLI</u>	CHI TOTAL HOLDEN				CANO	LLLATION				
3 (	UEST DIAGNOSTICS INCORPORATED BIRALDA FARMS ADISON, NJ 07940				THE	EXPIRATION	I DATE THE	ESCRIBED POLICIES BE CA REOF, NOTICE WILL E Y PROVISIONS.		
						IZED REPRESE 1 USA Inc.	NTATIVE			

Marea Viction

Marla Nicholson